Publications

Non-Refereed Journals

  1. Kanouse DE, Mathews WC, Bennett CL. Quality of Care Issues for HIV Illness. National Center for Health Services Research Symposium on AIDS/Quality and Cost Issues, Miami, FL; 1989.
  2. Pascal A, Bennett CL, Bennett RL, Cvitanic M. The Cost of AIDS in Los Angeles-Results of a Pilot Study. Proceedings of the National Center for Health Services Research Symposium on Costs and Quality of Care for AIDS; 1989.
  3. Gulati SC, Bennett CL, Prowda JB, Spanik S, Lemoli R. GM-CSF for Patients Undergoing Autologous Bone Marrow Transplantation. Molecular Biology of Haematopoiesis, Andover, England: Intercept Ltd., pp.385-390.
  4. Bennett CL, Roth CP, Iqbal A. Medical Record Abstraction Form and Guidelines for Assessing Quality of Care for Hospitalized Patients with AIDS-related Pneumocystis carinii Pneumonia. Agency for Health Care Policy and Research, N-3549; 1993.
  5. Bennett CL, Pajeau TS.  Costs of Care and Outcomes for High-Dose Therapy and Autologous Transplantation for Hodgkin's Disease and Non-Hodgkin's Lymphoma.  Topics in Support Care Oncology, 19:2-5, 1996.
  6. Pajeau TS, Bennett CL.  Preventing hepatitis B, hepatocellular cancer: made in Taiwan.  Oncology News International.  5(9), 1996.
  7. Weinberg P, Bennett CL.  Insurance Policies for Cancer: Made in Japan.  Oncology News International, 5 (7):1,6; 1996.
  8. Weinberg, PD, Bennett CL. Changing trends in Hemophilia Care.  HemAware, 2(2):24,26,34; 1997.
  9. Weinberg PD, Bennett CL. Securing the International Blood Supply Against HIV. Oncology News International, 5(12): 50-51 1996.
  10. Weinberg PD, Bennett CL.  New Strategies Needed to Monitor Blood Usage.  Oncology News International, 6(6): 1,8-9; 1997.
  11. Weinberg PD, Bennett CL.  Keeping the International Blood Supply Safe from HIV.  Prim Care Cancer. 17(8):6-8, 1997.
  12. Weinberg PD, Bennett CL.  Program Serves as Model for Addressing New Technology. Oncology News International, 6(10): 5,52; 1997.
  13. Bennett CL, Yang T, Nadler R. Variations in the use of prostate cancer staging tests: results from one NCCN institution. Oncology, NCCN Proceedings.  11(11A): 155-157, 1997.
  14. Weinstein JM, Bennett CL. Expect cultural differences in patient views on cancer. International quality of life studies.  Oncology News International.  6(8), 1997.
  15. Weinberg PD, Hornung RL, Bennett CL.  School skin cancer programs evolving to include computers.  Oncology News International.  7(3), 1998.
  16. Pajeau TS, Yang T, Lurain JR, Bennett CL.  Medicare Rule Raises Dilemma in Recurrent Ovarian Cancer.  Oncology News International, 7(2): 5, 33; 1998.
  17. Ferreira MR, Davis TC, Sartor O, Bennett CL.  Low Literacry Predicts Advanced Prostate Cancer Presentation.  Oncology News International, 7(10):3,16-17; 1998.
  18. Belani CP, Pajeau TS, Bennett CL.  Treating malignant pleural effusions cost consciously.  Chest. 113(1 Suppl): 78S-85S, 1998.
  19. Weinberg PD, Bennett CL.  Hematologists detect rare side effect of antiplatelet agent.  Oncology News International.  7(5), 1998.
  20. Shih L, Bennett CL. Oncologists split on CSF use in older AML patients.  Oncology News International.  7(8), 1998.
  21. Bennett CL, Stinson TJ, Yang T, Lurain JR. The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. Seminars in Oncology, 26(1 Suppl 1): 40-5, 1999.
  22. Wade JL III, Weinberg PD, Bennett CL.  Managed care’s effects on community clinical research.Oncology News International.  8(5), 1999.
  23. Bennett CL, Weinberg PO, Golub RM. Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Seminars in Hematology. 36(1 Suppl 2): 26-9, 1999.
  24. Kim SP, Bennett CL, Chan C, Chmiel J, Falcone D, Knight SJ, Chmiel J, Kuzel T, Davis TC, Elstein AS, Moran E, Robertson CN, Smith JS.  Quality of life and outcomes research in prostate cancer patients with low socioeconomic status.  Oncology.  13(6):828-32; discussion 835-8, 1999.
  25. Calhoun EA, Bennett CL. Pharmacoeconomics of Amifostine in ovarian cancer.  Seminars in Oncology. 26 (2 Suppl 7): 102-7, 1999.
  26. Tomori C, Sipler AM, Bennett CL. Women with at greater risk for cervical cancer.  How HPV induces cervical cancer. Oncology News International. 8(12): 2,22, 1999.
  27. Bennett CL, Lane DR.  Seminars in Respiratory Diseases: Large Database Studies of   HIV-Related Pneumocystis Carinii Pneumonia. Seminars in Respiratory Critical Care Med.
  28. Bennett CL, Weinberg PD, Golub RM, Bussel JB.  The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis.  Seminars in Hematology.  37(1 Suppl 1): 26-30, 2000.
  29. Sipler AM, Tomori C, Bennett CL. Does Bias Exist in Economic Analyses of New Agents? Managed Care & Cancer, 2(1): 26-31, 2000.
  30. Tomori C, Sipler AM, Bennett CL. Women with HIV are at greater risk for cervical cancer. Primary Care & Cancer, 20(4): 11-13, 2000.
  31. Sipler AM, Tomori C, Bennett CL. Pharmaceutical sponsored economic analyses: Can they be believed? Oncology Economics, 1(1): 32-33, 2000.
  32. Hounshell J, Knox K, Tomori C, Bennett CL.  Improving minority participation in prevention trials. Oncology News International, 9(9), 2000.
  33. Hounshell J, Knox K, Tomori C, Bennett CL.  Improving minority access to genetic counseling for cancer risk.  Oncology News International.  9(10), 2000.
  34. Slimack N, Tomori C, Bennett CL. Quality of life assessment in culturally diverse populations: A summary of findings from the 1999 Robert H. Lurie Comprehensive Cancer Center Health Policy Symposium. Oncology News International.  9(6), 2000.
  35. Adams JR, Tomori C, Bennett CL.  Improving health care for patients with low literacy skills. Oncology News International.  9(12), 2000.
  36. Knox K, Hounshell J, Tomori C, Bennett CL.  Culturally specific interventions can improve cancer screening among minorities. The witness project.  US-Mexican Border project.  Oncology News International.  9(8), 2000.
  37. Adams JR, Tomori C, Bennett CL.  Poor reading skills present barrier to cancer care and health. Oncology News International.  9(11), 2000.
  38. Adams JR, Tomori C, Bennett CL.  Poor reading skills present barrier to cancer care and health. Primary Care and Cancer.  21(4), 2001.
  39. Engebretson AJ, Tomori C, Bennett CL.  Access to care and quality of care ‘inseparable’ concepts. Oncology News International.  10(7), 2001.
  40. Tomori C, Angelos P, Bennett CL. Communication: from paternalism to shared decision-making. Oncology News International.  10(2), 2001.
  41. Engebretson AJ, Tomori C, Angelos P, Bennett CL. Bridging the cultural divide: cross-cultural issues in cancer care. Oncology News International. 10(4), 2001.
  42. Bennett CL. Choosing measures to evaluate the quality of cancer care.  Oncology News International. 10(5), 2001.
  43. Ali SN, Tomori C, Angelos P, Bennett CL. Beecher and beyond: informed consent in cancer trials. Oncology News International.  10(3), 2001.
  44. Adamczyk P, Tomori C, Bennett CL.  Exploring the hidden financial burden of cancer therapy. Oncology News International.  10(1), 2001.
  45. Slimack, N, Ladewski M, Tomori C, Bennett CL.  Guidelines help ensure quality of breast cancer care.  Oncology News International.  10(9), 2001.
  46. Adams, JR, Tomori C, Bennett CL.  Uncertainty in medicine: a talk with Dr. Djulbegovic.  Oncology News International.  10(11), 2001.
  47. Lee J, Calhoun E, Newlin RC, Bennett CL.  Assessing the Total Cost of Chemotherapy-Induced Toxicities.  Oncology News International.  11(3), 2002.
  48. Gibbons KC, Newlin RC, Phan L, Bennett CL.  HBV Vaccination Program Reduces Liver Cancer in Taiwan.  Oncology News International. 11(4), 2002.
  49. Newlin RC, Lee J, Bennett CL.  Financial and Lifestyle Impact of a Hairy Cell Leukemia Diagnosis. Oncology News International.  11(5), 2002.
  50. Bennett CL, Calhoun EA. Pharmacoeconomics of liposomal anthracycline therapy. Semin Oncol. 2004 Dec;31(6 Suppl 13):191-5.
  51. Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDS. 2006 May;20(5):359-68.
  52. McCaffrey KR, Angelotta C, Costello SR, Pickard AS, Schumock GT, Nau DP, McKercher PL, and Bennett CL. Importation of Prescription Medications: Community Pharmacists Take on Consumer Demand, Safety, and Economic Implications. Oncology News International. December 2005:48-49.
  53. Angelotta C and Bennett CL. In the wake of the storm: do electronic record systems improve patient safety? Oncology News International. February 2006; 36-42.
  54. Bennett CL, Angelotta C, Boothman R, and Blayney DW. Safety in Oncology: Adverse Event Surveillance and Malpractice Claims Reduction. 2006 Educational Book. American Society of Clinical Oncology. June 2006; 620-625.
  55. Angelotta C, Dorr D, and Bennett CL. Reporting Only ‘Unanticipated’ Aes of Trial Drugs Would Reduce IRB Workload, But Would Patient Safety Suffer? Oncology News International. November 2006;23.
    • Nonzee NJ, SamarasA, Calhoun EA, Bennett CL. $25 Million Patient Navigation Aims to Reduce Cancer Health Disparities in Targeted Communities. Oncology News International. 16 (4), 2007.

Refereed Journals

  1. Bennett CL, Vogelzang NJ, Ratain MJ, Reich SD.  Hyponatremia and other toxicities during a phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treatment Reports, 70(9): 1081-1084, 1986.
  2. Bennett CL, Bitran J, Recant W, Putterman A, Shapiro CM, Karesh J, Kalohke V.  Staging and therapy of orbital lymphomas. Cancer, 57(6): 1204-8; 1986.
  3. Bennett CL, Westbrook C, Bruber B, Golomb HM. Hairy cell leukemia and mucormycosis: A case Report. American J Medicine, 81(6): 1065-7, 1986.
  4. Bennett CL, Vardiman J, Golomb HM.  Atypical mycobacteria infection and hairy cell leukemia. American J Medicine, 80:891-895; 1986.
  5. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE.  Phase I clinical and pharmacologic study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Research, 47(7): 1952-1956; 1987.
  6. Bitran JD, Bekerman C, Ewinstein R, Bennett CL, Ryo U, Pinsky S.  Patterns of gallium-67 scintigraphy in patients with AIDS and the AIDS-related complex. J Nuc Medicine, 28:1103-1106; 1987.
  7. Pascal A, Cvitanic MA, Bennett CL, Gorman M, Serrato C. State policies and the financing of AIDS care. RAND Notes, N-2942-HCFA, 1989.
  8. Mathews WC, Ferdon E, Bennett CL, Kanouse D.  Evaluating institutional performance in AIDS- related Pneumocystis carinii Pneumonia: A risk-adjustment approach. J Clinical Epidemiology, 42:421-425; 1989.
  9. Pascal A, Cvitanic MA, Bennett CL.  Assessing the effects of state Medicaid and health insurance regulations on cost sharing for AIDS treatment expenses. Health Care Financial Review, 11:91-104; 1989.
  10. Bennett CL, Garfinkle JB, Greenfield S, Draper D, Rogers W, Mathews WC, Kanouse DE.  The relation between hospital experience and in-hospital mortality for patients with AIDS-related Pneumocystis carinii Pneumonia. JAMA, 261(20): 2975-9, 1989.
  11. Bennett CL, DeHovitz JA, Kessler H.  AIDS care needs wider QA effort.  QA Review.  1(5):6, 1989.
  12. Pascal A, Bennett CL, Cvitanic MA, Gorman M, Serrato C. The cost and financing of care for AIDS patients in Los Angeles. The RAND Corporation, N-3060-HCFA, 1990.
  13. Bennett CL, Pascal A, Cvitanic M, Graham V, Kitchens A, DeHovitz JA.  Medical care costs of intravenous drug users with AIDS in Brooklyn. The RAND Corporation, RP-102, 1992.
  14. Bennett CL, Gertler P, Guze PA, Garfinkle JB, Kanouse D, Greenfield S. The relation between resource use and in-hospital mortality for patients with AIDS-related Pneumocystis carinii pneumonia. Archives of Internal Medicine, 150(7): 1447-52, 1990.
  15. Bennett CL, Graf L, Hunter-Young N, Daley J, Makadon H.  Intensity of in-hospital care for persons with AIDS. J AIDS, 4(9): 856-60, 1991.
  16. Bennett CL, Dobratz N.  Medical care for AIDS: cost planning.  Journal of Healthcare Material Management.  9(8): 39-43, 1991.
  17. Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff R.  Patterns of care related to age of men with prostate cancer.  Cancer. 67(10): 2633-41, 1991.
  18. Bennett CL, Cvitanic MA, Pascal A. The Costs of AIDS in Los Angeles.  J AIDS, 4(2):197-203, 1991.
  19. Bennett CL, Chang H, Shlian D, Dawson JA, Edlin BR.  Health care use by HIV-infected students at a California student health service.  Western J Medicine, 157(1): 41-43, 1992.
  20. Bennett CL, Pascal A, Cvitanic M.  Medical care costs of intravenous drug users with AIDS in Brooklyn.  J AIDS, 5(1): 1-6, 1992.
  21. Bennett CL, Adams J, Gertler P. The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP: Experience with 3,126 cases in New York City in 1987. J AIDS, 5(9): 856-64, 1992.
  22. Gulati SC, Bennett CL.  Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed Hodgkin Disease.  Annals of Internal Medicine, 116(3): 177-82, 1992.
  23. Abaloufia DM, Bennett CL, Koga H, Keith D, Salmon D. Human T-cell leukemia virus type I/II serologic testing: the importance of assaying for the full complement of viral antigens.  Viral Immunology J, 5:105-12, 1992.
  24. Albert A, Bennett CL, Bojar M.  Health care in the Czech republic: a system in transition.  JAMA, 267:2461-6, 1992.
  25. Gulati S, Bennett CL, Gopal A, Gopal R.  Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin’s disease. Anti-Cancer Drugs, 4:13-6, 1993.
  26. Ganz PA, Bennett CL, Berek J. The physician as the patient's advocate.  J Clinical Oncology, 11:1011-3, 1993.
  27. Bennett CL, Deneffe D.  Does experience improve hospital performance in treating patients with AIDS?  Health Policy, 24(1): 35-43, 1993.
  28. Bastian L, Bennett CL, Adams J, Waskin H, Divine G, Edlin BR.  Differences between men and women with HIV-related Pneumocystis carinii Pneumonia: experience from 3,070 cases in New York City in 1987.  J AIDS, 6(6): 617-23, 1993.
  29. Lubeck D, Bennett CL, Mazonson P.  Quality of life and health service utilization among HIV- infected patients with chronic diarrhea.  J AIDS, 6(5): 478-84, 1993.
  30. Bennett CL, Schwartz G, Marberger M.  Health care in Austria: Universal access, national health insurance, and private health care.  JAMA, 269(21): 2789-94, 1993.
  31. Gulati S, Bennett CL, Phillips J, Van-Poznak C.  GM-CSF as an adjunct to autologous bone marrow transplantation.  Stem Cells, 11:20-25; 1993.
  32. Bennett RL, Gilman SC, George L, Guze PA, Bennett CL. Improved outcomes in intensive care units for AIDS-related Pneumocystis carinii Pneumonia: 1987-1991.  J AIDS, 6(12): 1319-21, 1993.
  33. Abaloufia DM, Feigal E, Vranzian K, Bennett CL, Blattner W, Moss A, Slamon D.  Human T-cell leukemia virus serodiagnostic testing: Disparate results among a cohort of intravenous drug users. AIDS Research and Human Retroviruses, 9:1043-50, 1993.
  34. Ozer H, Miller LL, Anderson JR, Anderson PN, Armitage JO, Beckhardt S, Bennett CL, Bodey GP, Crawford J, Davidson NE, Demetri GD, Hamm JT, Hillner B, Kardinal CG, Levine MN, Miller JA, Ochs JJ, Santana VM, Schiffer CA, Shea TC, Smith TJ, Vadhan-Raj S, WadeJL, Weeks JC, Winn  RJ.  American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony- stimulating factors: evidence-based, clinical practice guidelines.J Clin Oncol, 12(11):2471-508, 1994.
  35. Bennett CL, Armitage JL, Buchner D, Gulati S.  Economic analysis in phase III clinical cancer trials. Cancer Investigation, 12(3): 336-42, 1994.
  36. Bennett CL, Armitage JL, LeSage S, Gulati S, Armitage JO, Gorin C.  Economic analyses of clinical trials in cancer: are they helpful to policy makers?  Stem Cells, 12(4):424-9, 1994.
  37. Bennett CL, DeHovitz JA, Cassileth BR. Interpreting hospital mortality for AIDS: What can we learn from mortality studies of patients without AIDS? Clin Perform Qual Health Care, 2:154-8, 1994.
  38. Hermanson T, Aro S, Bennett CL. Finland's health care system: Universal access to health care in a capitalistic democracy. JAMA, 271(24): 1957-62, 1994.
  39. Bennett CL, Weinstein RA, Shapiro MF, Kessler H, Dickinson G, Peterson B, Cohn SE, George WL, Gilman SA. A rapid pre-administration method for predicting inpatient course of disease for patients with HIV-related Pneumocystis carinii Pneumonia. American J Resp Crit Care Med, 150(6 Pt 1): 1503-07, 1994.
  40. Bennett CL, Adams J, Bennett RL, George L, Cassileth B, Gilman SC. The learning curve for AIDS-related Pneumocystis carinii Pneumonia: experience from 3,981 cases in Veterans Affairs Hospitals 1987-1991. J AIDS. 8(4): 373-8, 1995.
  41. Bennett CL, Lubeck DP, McShane DJ, Matthews JK, Lipil WH.  Costs of terminal care for people with AIDS. AIDS Patient Care.  9(1): 7-9, 1995.
  42. Bennett CL, Armitage JL, Armitage GO, Vose JM, Bierman PJ, Armitage JO, Anderson JR.  Costs  of care and outcome for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.   J Clinical Oncology. 13(4): 969-73, 1995.
  43. Bennett CL, Cassileth BR, DeHovitz JA, Weinstein RA.  Score Cards for AIDS Care. J AIDS, 9(3): 286-90, 1995.
  44. Moore M, Bennett CL. The learning curve for laparoscopic cholecystectomy. The Southern Surgeons Club. American Journal of Surgery, 170(1): 55-9, 1995.
  45. Albert A, Bennett CL.  Condom Use Among Sex Workers in Las Vegas.  American J Public Health. 85: 1514-20, 1995.
  46. Clipp EC, Adinolfi AJ, Forrest L, Bennett CL.  Informal caregivers of persons with AIDS.  Journal of Palliative Care, 11(2): 10-8, 1995.
  47. Bennett CL, Horner RD, Weinstein RA. Racial differences in care among hospitalized patients with Pneumocystis carinii Pneumonia in Chicago, New York, Los Angeles, Miami, and Raleigh.  Archives of Internal Medicine. 155(15): 1586-92, 1995.
  48. Horner RD, Bennett CL, Weinstein RA.  Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii Pneumonia. American Journal of Respiratory and Critical Care Medicine. 152(5 Pt 1): 1435-42, 1995.
  49. Oken C, Archibald N, Cvitanic M, Biddle A, Shapiro MF, Bennett CL.  Multi-city study of quality of care for HIV-related Pneumocystis carinii Pneumonia: Successfully collecting highly sensitive information.  Clinical Performance and Quality Health Care. 3(3): 140-6, 1995.
  50. Bennett CL, George SL, Hillner B, Fleishman S, Neill B.  Free riding and the prisoner’s dilemma: problems in funding economic analyses of phase III cancer clinical trials.  J Clinical Oncology, 13(9): 2457-63, 1995.
  51. Bennett CL, Horner RD, Weinstein RA, Kessler HA, Dickenson GM, Pitrack DL, Gillman SC, George WL, Cohn SE, Simberkoff MS. Empirically treated Pneumocystis carinii Pneumonia in Los Angeles, Chicago, and Miami: 1987-1990. Journal of Infectious Diseases. 172(1): 312-5, 1995.
  52. Bennett CL, George SL, Vose JM, Neumunaitis JJ, Armitage JL, Armitage JO, Gorin NC, Gulati   SC. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed lymphoid malignancy: Economic analyses of phase III clinical trials. Stem Cells. 13(4): 414-20, 1995.
  53. Bennett CL, Horner RD, Abaloufia D, Weinstein RA.  Patterns of care for and outcomes of Pneumocystis carinii Pneumonia among persons with transfusion-acquired AIDS. Transfusion, 35(8): 674-8, 1995.
  54. Hillner BE, McCleod VG, Crawford ED, Bennett CL. Estimating the cost-effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology. 45(4): 633-40, 1995.
  55. Bennett CL, Oddone E, Matchar D. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii Pneumonia: Are they helpful to policy makers? Clinical Performance and Quality Health Care. 3(3): 156-64, 1995.
  56. Bennett CL, Westerman IL. Economic analysis during phase III clinical trials: who, what, when, where, and why? Oncology. 9(11 Suppl): 169-75, 1995.
  57. Arno PS, Bonuck KA, Green J, Fleishman J, Bennett CL, Fahs MC, Maffeo C, Drucker E.  The impact of housing status on health care utilization among persons with HIV disease.  J Health Care for the Poor and Underserved. 7(1): 36-49, 1996.
  58. Bonock KA, Arno PS, Green J, Fleishman J, Bennett CL, Fahs MC, Maffeo C.   Self-perceived unmet health care needs of persons enrolled in HIV care. J Community Health. 21(3): 183-98, 1996.
  59. Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effectiveness models of flutamide for prostate cancer: Are they helpful to policy makers?  Cancer 77(9):1854-61, 1996.
  60. Ullman M, Metzger CK, Kuzel TM, Bennett CL.  Performance measurement in prostate cancer treatment: beyond report cards.  Urology. 47(3): 356-65; 1996.
  61. Zarkin GA, Bala MV, Wood LL, Bennett CL, Simpson K, Dohn MN. Estimating the cost- effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia patients. Pharmacoeconomics. 9(6): 525-34, 1996.
  62. Bennett CL, Curtis JR, Achenbach C, Arno P, Bennett R, Fahs MC, Horner RD, Shaw-Taylor Y, Andrulis D.  U.S. hospital care for HIV-infected persons and the role of public, private, and Veterans Administrations Hospitals.  J AIDS. 13(5): 416-21, 1996.
  63. Horner RD, Bennett CL, Achenbach C, Rodriguez D, Adams J, Gilman SC, Cohn SE, Dickinson GM, DeHovitz JA, Weinstein RA.  Predictors of resource utilization for hospitalized patients with PCP:  a summary of effects from the multi-city study of quality of PCP care.  J AIDS. 12(4): 379-85, 1996.
  64. Bennett CL, Pei G, Ultmann JE.  Western impressions of the Hong Kong health care system.Western Journal of Medicine. 165:37-42, 1996.
  65. Westerman IL, Bennett CL.  A review of the costs, cost-effectiveness, and third party charges of bone marrow transplantation.  Stem Cells, 14(3): 312-9, 1996.
  66. Chen DS, Hsu HM, Bennett CL, Pajeau TS, Blumberg B, Chang PY, Nishioka K, Huang A, Sung, JL.  A program for eradication of hepatitis B from Taiwan by a ten-year, four-dose vaccination program. Cancer Causes and Control, 7(3): 305-11, 1996.
  67. Bennett CL, Ullman M, Dickinson GM, Horner RD, Feinglass J, Weinstein RA, Curtis JR.  Patterns of care for HIV-related Pneumocystis carinii pneumonia in a university medical program: a case study.  Clinical Performance and Quality Health Care, 4(4): 186-9, 1996.
  68. Bennett CL, Smith TJ, Weeks JC, Bredt AB, Feinglass J, Fetting JH, Hillner BE, Somerfield M, Winn RJ.  Use of hematopoietic colony stimulating factors: The American Society of Clinical Oncology Survey.  J Clinical Oncology, 14(9): 2511-20, 1996.
  69. Keitz SA, Bastian LA, Bennett CL, Oddone EZ, DeHovitz JA, Weinstein RA.  AIDS-Related Pneumocystis carinii Pneumonia in older patients.  J General Internal Medicine. 11(10):591-6, 1996.
  70. Cohn SE, Klein JD, Weinstein RA, Shapiro MF, DeHovitz JA, Kessler HA, Dickinson GM, Rodriguez DC, Bennett CL.  Geographic variation in the management and outcome of patients with AIDS-related Pneumocystis carinii Pneumonia. JAIDS. 13(5): 408-15, 1996.
  71. Waters TM, Bennett CL, Vose JM.  Economic analyses of new technologies: the case of stem-cell transplantation. J Clinical Oncology. 15(1): 2-4, 1997.
  72. Cegielski JP, Goetz MB, Jacobson JM, Cohn SE, Weinstein RA, DeHovitz JA, Bennett CL.  Gender differences in early suspicion of tuberculosis in hospitalized, high-risk patients during four epidemic years. Infection Control and Hospital Epidemiology. 18(4): 237-242, 1997.
  73. Tulsky JA, Cassileth BR, Bennett CL.  The effect of race on ICU use and DNR orders in hospitalized AIDS patients.  J Clinical Ethics. 8(2): 150-7, 1997.
  74. Yarnold PR, Soltysik RC, Bennett CL.  Predicting in-hospital mortality of patients with AIDS- related Pneumocystis carinii pneumonia: an example of hierarchically optimal classification tree analysis. Statistics in Medicine, 16(13): 1451-63, 1997.
  75. Bennett CL, Stryker SJ, Ferreira MR, Adams J, Beart RW. The learning curve for laparoscopic colorectal surgery: preliminary results from a prospective analysis of 1194 laparoscopic-assisted colectomies.  Archives of Surgery. 132(1): 41-4, 1997.
  76. Matchar DB, McCrory DC, Bennett CL.  Treatment considerations for persons with metastatic prostate cancer: survival versus out-of -pocket costs.  Urology. 49(2): 218-24, 1997.
  77. Bennett CL, Golub R, Waters TM, Tallman MS, Rowe JM.  Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?  Cancer Investigation, 15(3): 227-36, 1997.
  78. Bennett CL, Waters TM.  Economic analyses in clinical trials for cooperative groups: operational considerations.  Cancer Investigation. 15(5): 448-53, 1997.
  79. Crawford ED, Bennett CL, Stone NN, Knight SJ, DeAntoni E, Sharp L, Garnick MB, Porterfield HA.  A comparison of patient and physician perspectives on prostate cancer: analyses of survey data. Urology. 50(3): 366-72, 1997.
  80. Bennett CL, Buchner DA, Ullman M.  Approaches to prostate cancer by managed care organizations. Urology. 50(1): 79-86, 1997.
  81. Curtis JR, Ullman M, Collier AC, Krone MR, Edlin BR, Bennett CL.  Variations in medical care for HIV-related Pneumocystis carinii pneumonia: A comparison of process and outcome at two  hospitals. Chest. 112(2): 398-405, 1997.
  82. Bennett CL, Chapman G, Elstein AS, Knight SJ, Nadler RB, Sharifi R, Kuzel T.  A comparison of patient and physician perspectives on prostate cancer:  analyses of utility assessments of patients and physicians.  European J of Urology. 32(Suppl 3): 86-8, 1997.
  83. Bennett CL, Yang T, Nadler R.  Variations in the use of prostate cancer staging tests: results from one NCCN institution.  Oncology.  11(11A): 155-7, 1997.
  84. Bastian LA, Bennett CL, Weinstein RA, Sloane RJ, DeHovitz JA, Kessler HA.  Gender differences in care for AIDS-related Pneumocystis carinii pneumonia. Womens Health Issues. 8(1): 45-52, 1998.
  85. Bennett CL, Weinberg PD, Lieberman JJ.  Cancer insurance policies in Japan and in the United States.  Western J of Medicine, 168(1): 17-22, 1998.
  86. Bennett CL, Golub RM, Calhoun EA, Weinstein J, Fishman D, Lurain J, Roland P, Medio F, Bukowski RM.  Cost utility assessment of amifostine as first-line therapy for ovarian cancer. International J Gynecologic Cancer. 8:64-72, 1998.
  87. Chapman GB, Elstein AS, Kuzel TM, Sharifi R, Nadler R, Andrews A, Bennett CL.  Prostate cancer patients' utility for health states:  how it looks depends on where you stand.  Medical Decision Making. 18(3): 278-86, 1998.
  88. Josephson MA, Agger WA, Bennett CL, Ullman M, Arnow PM.  Performance measurement in pneumonia care:  beyond report cards.  Mayo Clinic Proceedings. 73(1): 5-9, 1998.
  89. Waters TM, Weinberg PD, Bennett CL.  Health economics in the treatment of colorectal cancer. Cancer Investigation. 16(8): 582-7, 1998.
  90. Waters TM, Bennett CL, Pajeau TS, Sobocinski KA, Klein JP, Rowlings PA, Horowitz MM. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know?  Bone Marrow Transplantation. 21(7): 641-50, 1998.
  91. Bennett CL, Golub RM, Stinson TJ, Aboulafia DM, von Roenn J, Bogner J, Goebel FD, Stewart S. Cost effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi’s sarcoma. J AIDS. 18(5): 460-5, 1998.
  92. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PL, Kwaan HC, Green D.  Thrombotic thrombocytopenic purpura associated with ticlopidine:  A review of 60 cases.  Annals of Internal Medicine, 128(7): 541-4, 1998.
  93. Curtis JR, Bennett CL, Horner RD, Rubenfeld GD, DeHovitz JA, Weinstein RA. Variations in ICU utilization for patients with HIV-related Pneumocystis carinii pneumonia: the importance of hospital characteristics and geographic location.  Critical Care Medicine, 26(4): 668-75, 1998.
  94. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, Seday MA, Sartor O. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clinical Oncology. 16(9): 3101-4, 1998.
  95. Shortell SM, Bennett CL, Byck GR. Assessing the impact of continuous quality improvement on clinical practice: what it will take to accelerate progress. Millbank Quarterly. 76(4): 593-624, 510, 1998.
  96. Bennett CL, Kiss JE, Weinberg PD, Pinevich AJ, Green D, Kwaan HC, Feldman MD. Thrombotic thrombocytopenic purpura after stenting and ticlopidine.  Lancet. 352(9133): 1036-7, 1998.
  97. Knight SJ, Chmiel JS, Kuzel T, Sharp L, Albers M, Fine R, Moran EM, Nadler RB, Sharifi R, Bennett CL. Quality of life in metastatic prostate cancer among men of lower socioeconomic status: Feasibility and criterion related validity of three measures.   J Urology. 160(5): 1765-9, 1998.
  98. Calhoun EA, Bennett CL, Peeples PA, Lurain JR, Roland PY, Weinstein JM, Fishman DA. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecologic Oncology. 71(3): 369-75, 1998.
  99. Stinson TJ, Calhoun EA, Yang T, Lurain JR, Bennett CL. Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.  Cancer Investigation.  17(8): 559-65, 1999.
  100. Bennett CL, Stinson TJ, Tallman MS, Stadtmauer EA, Marsh RW, Friedenberg W, Lazarus HM, Kaminer L, Golub RM, Rowe JM.  Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia.  Eastern Cooperative Oncology Group (E1490).  Annals of Oncology. 10(2): 177-82, 1999.
  101. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen- blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer and Prostatic Diseases, 2:4-8, 1999.
  102. Ferreira MR, Bennett RL, Gilman S, Mathewson S, Bennett CL. Diffusion of laparoscopic cholecystectomy in the Veterans Affair health care system: 1991-1995. Effective Clinical Practice. 2(2): 49-55, 1999.
  103. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL. A multi-attribute model of prostate cancer patients’ preferences for health states. Quality of Life Research. 8(3): 171-80, 1999.
  104. Arozullah AM, Ferreira MR, Bennett RL, Gilman S, Henderson WG, Daley J, Kuhri S, Bennett CL. Racial variations in the use of laparoscopic cholecystectomy in the Department of Veterans Affairs medical system. J American College of Surgeons. 188(6): 604-22, 1999.
  105. Bennett CL, Stinson TJ. Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the GOG 111 trial. Cancer Investigation.  108:263-70, 1999.
  106. Bennett CL, Waters TM, Stinson TJ, Almagor O, Pavletic ZS, Tarantolo SR, Bishop MR. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 24:555-60, 1999.
  107. Mighion K, Gesme DH, Rifkin RM, Bennett CL. Growth of oncology physician practice management companies. Cancer Investigation.  17(5): 362-70, 1999
  108. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke Prevention. Archives of Internal Medicine. 159(21): 2524-8, 1999.
  109. Sharp LK, Knight SJ, Nadler R, Albers M, Moran E, Kuzel T, Sharifi R,  Bennett CL. Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Quality of Life Research. 8:461-70, 1999.
  110. Freeman MB, Vose JM, Bennett CL, Anderson JR, Kessinger A, Turner K, Pierson J, Bishop M, Bierman P, Armitage JO. Costs of care for high-dose therapy and autologous transplantation for non- Hodgkin’s lymphoma: results from the University of Nebraska Medical Center 1989 through 1995. Bone Marrow Transplant. 24: 679-684, 1999.
  111. Bach PB, Calhoun EA, Bennett CL. Identifying providers of care to individuals with human immunodeficiency virus for a mail survey using a prescription-tracking database. J Clinical Epidemiology. 52(2): 147-50, 1999.
  112. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.  JAMA. 282(15): 1453-7, 1999.
  113. Bennett CL, Weeks J, Somerfield MR, Feinglass J, Smith TJ.  Use of hematopoietic colony stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines.  Health Services Research Committee of the American Society of Clinical Oncology.  J Clinical Oncology.  17(11): 3676-81, 1999.
  114. Bach PB, Calhoun EA, Bennett CL. The relation between physician experience and patterns of care for patients with AIDS-related Pneumocystis carinii pneumonia: results from a survey of 1,500 physicians in the United States.  Chest.  115(5): 1563-9, 1999.
  115. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett CL, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S. Review: An evidence-based analysis of the effect  of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia.  Blood, 94:1517-36, 1999.
  116. Dale W, Sartor O, Davis T, Bennett CL.  Understanding barriers to the early detection of prostate cancer among lower socioeconomic men. Prostate Journal, 1: 179- 184, 1999.
  117. Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. The association between physician reimbursement in the United States and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American society of Clinical Oncology survey.  Annals of Oncology. 10(11): 1355-9, 1999.
  118. Bennett CL, Stinson TJ.  Does reimbursement affect physician decision-making?  Cancer Treatment and Research.  102:137-49, 2000.
  119. Bennett CL, Stinson TJ.  Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial.  Cancer Investigation. 18(3): 261-8, 2000.
  120. Bennett CL, Stinson TJ, Lane D, Amylon M, Land VJ, Laver JH.  A cost-analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoma: a case for prospective economic analysis in cooperative group trials. Medical and Pediatric Oncology. 34(2): 92-6, 2000.
  121. Bennett CL, Stinson TJ, Laver JH, Bishop MR, Godwin JE, Tallman MS. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision-making. Leukemia and Lymphoma. 37(1-2): 65-70, 2000.
  122. Manangan LP, Bennett CL, Tablan N, Simonds DN, Pugliese G, Collazo E, Jarvis WR. Nosocomial tuberculosis prevention measures among two groups of U.S. hospitals, 1992 to 1996. Chest. 117(2): 380-4, 2000.
  123. Bennett CL, Schwartz DN, Parada JP, Sipler AM, Chmiel JS, DeHovitz JA, Goetz MB, Weinstein RA.  Delays in tuberculosis isolation and suspicion among persons hospitalized with HIV-related pneumonia. Chest.  117(1): 110-6, 2000.
  124. Arozullah AM, Yarnold PR, Weinstein RA, Nwadiaro N, McIlraith TB, Chmiel JS, Sipler AM, Chan C, Goetz MB, Schwartz DN, Bennett CL.  A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early-HAART era. American J Respiratory and Critical Care Medicine.  161(4 Pt 1) 1081-6, 2000.
  125. Nadler RB, Koch LE, Calhoun EA, Campbell PL, Pruden DL, Bennett CL, Yarnold PR, Schaeffer AJ. IL-1beta and TNF-alpha in prostatic secretions are key indicators in the evaluation of men with chronic prostatitis. J Urology. 164(1): 214-8, 2000.
  126. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ.  Single- therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta- analysis.  Annals of Internal Medicine, 132(7): 566-77, 2000.
  127. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Michalets EL, Feldman MD, Davidson CJ, Tsai H.  Thrombotic thrombocytopenic purpura associated with clopidogrel.  New Engl J Med.  342(24): 1773-7, 2000.
  128. Bennett CL, Stinson TJ, Vogel V, Robertson L, Leedy D, O’Brien P, Hobbs J, Sutton T,  Ruckdeschel JC, Chirikos TN, Weiner RS, Ramsey MM, Wicha MS. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/ Northwestern University clinical trials costs and charges project.  J Clinical Oncology. 18(15): 2805-10, 2000.
  129. Randall CJ, Yarnold PR, Schwartz DN, Weinstein RA, Bennett CL.  Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. American J Respiratory and Critical Care Medicine. 162(2 Pt 1): 393-8, 2000.
  130. Cangliose CB, Blair AE, Borchardt JS, Ades TB, Bennett CL, Dickersin K, Gesme DH Jr., Henderson IC, McGinnis LS Jr., Mooney K, Mortenson LE, Sperduto P, Winkenwerder W Jr., Ballard DJ.  Purchasing oncology services.  Kerr L. White Institute/ American Cancer Society Task Force on Purchasing Oncology Services.  Cancer.  88(12): 2876-86, 2000.
  131. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfield MR, American Society of Clinical Oncology.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.  American Society of Clinical Oncology Growth Factors Expert Panel. J Clinical Oncology. 18(20): 3558-85, 2000.
  132. Fitzner K, Coughlin S, Tomori C, Bennett CL. Health care in Hong Kong and mainland China: one country, two systems? Health Policy.  53(3): 147-55, 2000.
  133. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GM. The uncertainty principle and industry-sponsored research. Lancet. 356 (9230): 635-8, 2000.
  134. Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Bennett CL. Quality and Dissemination of Industry Sponsored Economic Analyses of Six Novel Drugs Used in Oncology. Annals of Oncology. 11: 1591-1595, 2000.
  135. Djulbegovic B, Bennett CL, Adams JR, Lyman GH. Industry-sponsored research. Lancet. 356: 2193-2194, 2000.
  136. Stinson TJ, Adams JR, Bishop MR, Kruse S, Tarantolo S, Bennett CL. Economic Analysis of a Phase III Study of G-CSF versus Placebo Following Allogeneic Blood Stem Cell Transplantation. Bone Marrow Transplantation.  26(6): 633-66, 2000.
  137. Bennett CL, Weinberg PD, Golub RM, Bussell JB. The Potential for Treatment of Idiopathic Thrombocytopenic Purpura with Anti-D to Prevent Splenectomy: A Predictive Cost Analysis. Seminars in Hematology, 37(1): 26-30, 2000.
  138. Schmitt B, Bennett CL, Seidenfeld J, Samson D, Wilt T.  Maximal androgen blockade for advanced prostate cancer.  Cochrane Database of Systematic Reviews, (2): CD001526, 2000.
  139. Thrasher JB, Deeths J, Bennett CL, Iyer P, Dineen MK, Zhai S, Figg WD, McLeod DG. Comparative study of the clinical efficacy of two dosing regimens of flutamide.  Molecular Urology, 4(3): 259-63, discussion 265, 2000.
  140. Kim SP, Moran EM, Bowes ED, Tennant AG, Bennett CL. The Anti-Androgen Transfer. The Prostate Journal, 2(2): 88-93, 2000.
  141. Engebretson AJ, Tomori C, Angelos P, Bennett CL. Bridging the cultural divide: cross-cultural issues in cancer care. Primary Care and Cancer.  21(7), 2001
  142. Kim SP, Knight SJ, Tomori C, Colella KM, Schoor RA, Shih L, Kuzel TM, Nadler RB, Bennett CL. Health literacy and shared decision making for prostate cancer patients with low socioeconomic  status.  Cancer Investigation.  19(7): 684-91, 2001.
  143. Bennett CL, Hynes D, Godwin J, Stinson TJ, Golub RM, Appelbaum FR, Southwest Oncology Group. Economic analysis of granulocyte colony stimulating as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Investigation.  19 (6): 603-10, 2001.
  144. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH, American Society of Clinical Oncology.  Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.  J Clinical Oncology. 19(5): 1519-38, 2001.
  145. Kies MS, Bennett CL, Vokes EE. Locally advanced head and neck cancer.  Current Treatment Options in Oncology, 2(1): 7-13, 2001 February.
  146. Lindau ST, Tomori C, McCarville MA, Bennett CL. Improving rates of cervical cancer screening and Pap smear follow-up for low income women with limited health literacy. Cancer Investigation. 19(3): 316-23, 2001.
  147. Davis TC, Dolan NC, Ferreira MR, Tomori C, Green KW, Sipler AM, Bennett CL. The role of inadequate health literacy skills in colorectal cancer screening. Cancer Investigation. 19(2), 2001.
  148. Bennett CL, Lane D, Stinson T, Glatzel M, Büntzel J.  Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.  Cancer Investigation, 19 (2): 107-13, 2001.
  149. Knight SJ, Chmiel JS, Sharp LK, Kuzel T, Nadler RB, Fine R, Moran EM, Sharifi R, Bennett CL. Spouse ratings of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: an assessment of feasibility, reliability, and validity.   Urology, 57(2): 275-80, 2001.
  150. Schmitt B, Wilt TJ, Schellhamer PF, DeMasi V, Sartor O, Crawford ED, Bennett CL.  Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology, 57 (4): 727-32, 2001.
  151. Kim B, Lyons TM, Parada JP, Uphold CR, Yarnold PR, Hounshell JB, Sipler AM, Goetz MB, DeHovitz JA, Weinstein RA, Campo RE, Bennett CL.  HIV-related Pneumocystis carinii pneumonia in older patients hospitalized in the early HAART era.  J General Internal Medicine, 16(9): 583-9, 2001.
  152. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, Gordon MS, Lichtin AE, Wade JL III, Woolf S, Aronson N.  Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials.  J National Cancer Institute, 93(16): 1204-14, 2001.
  153. Adams JR, Ali SN, Bennett CL. Pricing, Profits, and Pharmacoeconomics--for whose benefit? Expert Opinion in Pharmacotherapy, 2(3): 377-383, 2001.
  154. Kim SP, Knight SJ, Tomori C, Colella KM, Schoor RA, Shih L, Kuzel TM, Nadler RB, Bennett CL. Health literacy and shared decision making for prostate cancer patients with low socioeconomic  status.  Cancer Investigation, 19(7):684-91, 2001.
  155. Hounshell J, Tomori C, Newlin R, Knox K, Rundhaugen L, Tallman M, Bennett CL. Changes in finances, insurance, employment, and lifestyle among persons diagnosed with hairy cell leukemia. The Oncologist. 6:435-440, 2001.
  156. Calhoun EA, Chang C-H, Welshman E, Fishman DA, Lurain JR, Bennett CL. Evaluating the total costs of chemotherapy-induced Neutropenia: results from a pilot study with ovarian cancer patients. The Oncologist, 6:441-445, 2001.
  157. Bennett CL, Adams JR, Knox KS, Kelahan AM, Silver SM, Bailes JS. Clinical trials: Are they a good buy?  J Clinical Oncology, 19 (23):  4330-4339, 2001.
  158. Djulbegovic B, Adams JR, Lyman GH, Lacevic M, Hozo I, Greenwich M, Bennett CL. Evaluation and appraisal of randomized controlled trials in myeloma. Annals of Oncology, 12:1611-1617, 2001.
  159. Lindau ST, Tomori C, Lyons T, Langseth L, Bennett CL. The association of health literacy with cervical cancer prevention knowledge and health behaviors in a multi-ethnic cohort of women. American Journal of Obstetrics and Gynecology, 186(5): 938-43, 2001.
  160. Morrow M, Venta L, Stinson T, Bennett CL.  Prospective comparison of Stereotactic core biopsy and surgical excision as diagnostic procedures for breast cancer patients.  Annals of Surgery, 233(4): 537-41, 2001.
  161. Weinberg PD, Hounshell J, Sherman L, Godwin J, Ali S, Tomori C, Bennett CL. Legal, Financial, and public health consequences of HIV-contamination of blood and blood products in the 1980s and 1990s. Annals of Internal Medicine, 136(4): 312-319, 2002.
  162. Bennett CL, Crane JM, ASCO Task Force on Quality of Cancer Care.  Quality improvement efforts in oncology: are we ready to begin?  Cancer Investigation, 19(1): 86-95, 2001.
  163. Feinglass J, Adams JR, Djulbegovic B, Bennett CL, Lyman GH. G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opinion on Pharmacotherapy, 3(9): 1273 – 1281, 2002.
  164. Adams JR, Nathan DP, Bennett CL. Pharmacoeconomics of therapy for ITP: steroids, IVIg, anti-D, and splenectomy.  Blood Reviews.  16: 65-67, 2002.
  165. Smith DH, Adams JR, Johnston SRD, Gordon A, Drummond MF, Bennett CL. A Comparative Economic Analysis of Pegylated Liposomal Doxorubicin versus Topotecan in Ovarian Cancer in the United States and United Kingdom. Annals of Oncology, 13:1590-1597, 2002.
  166. Evens AM, Kwaan HC, Kaufman DB, Bennett CL. TTP/HUS Occurring in a Simultaneous Pancreas/Kidney Transplant Recipient after Clopidogrel Treatment: Evidence of a Nonimmunological Etiology.  Transplantation, 74(6): 885-7, 2002.
  167. Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, Stadler W. Thalidomide- Associated Deep Vein Thrombosis and Pulmonary Embolism. American Journal of Medicine, 113:603-606, 2002.
  168. Johnson S, Chan J, Bennett CL.  Hepatotoxicity after Prophylaxis with a Nevirapine-Containing Antiretroviral Regimen.  Annals of Internal Medicine, 137(2): 146-147, 2002.
  169. Bennett CL, Raisch DW, Sartor O. Pneumonitis associated with the non-steroidal anti-androgens, bicalutamide, flutamide, and nilutamide: Presumptive evidence of a class effect.  Annals of Internal Medicine, 137(7): 625, 2002.
  170. Bennett CL, Price DK, Kim SP, Liu D, Jovanovic BD, Nathan DP, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD.  Racial Variations in CAG Repeat Lengths within the Androgen Receptor Gene among Prostate Cancer Patients of Lower Socioeconomic Status.  Journal of Clinical Oncology, 20(17): 3599-3604, 2002.
  171. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American society of clinical oncology and the American society of hematology.  J Clinical Oncology, 20(19): 4083-4107, 2002.
  172. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.  Blood, 100(7): 2303-20, 2002.
  173. Knight SJ, Nathan DP, Siston AK, Kattan MW, Elstein AS, Collela KM, Wolf MS, Slimack NS, Bennett CL, Golub RM.  Pilot Study of Utilities-Based Treatment Decision Intervention for Prostate Cancer Patients. Clinical Prostate Cancer, 1(2): 105-114, 2002.
  174. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL. Systematic Review and Meta-analysis of Monotherapy Compared with Combined Androgen Blockade for Patients with Advanced Prostate Carcinoma.  Cancer, 95(2): 361-76, 2002.
  175. Golub R, Adams J, Dave S, Bennett CL. Cost-effectiveness considerations in the treatment of essential Thrombocythemia.  Seminars in Oncology, 29(3 Suppl. 10): 28-32, 2002.
  176. Adams JR, Lyman GH, Djulbegovic B, Feinglass J, Bennett CL.  G-CSF as prophylaxis of febrile Neutropenia in SCLC. Expert Opinion in Pharmacotherapy, 3(9): 1273-81, 2002.
  177. Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A, O’Gara K, Rademaker A, Bennett CL, Winter JN.  Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplantation, 30: 741-748, 2002.
  178. Bennett CL. Cost analyses of granulocyte colony stimulating factor (G-CSF): a focus on older patients with cancer. Critical Reviews in Oncology and Hematology, 48(Suppl):S71-4, 2003.
  179. Siston AK, Knight SJ, Slimack NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharifi R, Bennett CL. Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology, 61: 172-78, 2003.
  180. Bennett CL, Somerfield MR, Pfister DG, Tomori C, Yakren S, Bach PB.  Perspectives on the Value of ASCO Clinical Guidelines as Reported by Oncologists and Health Maintenance Organizations. Journal of Clinical Oncology, 21:937-41, 2003.
  181. Calhoun EA, Bennett CL. Evaluating the Total Costs of Cancer: The Northwestern University Costs of Cancer Program.  Oncology, 17(1):109-14; discussion 119-21, 2003.
  182. MacDonald LA, Meyers S, Bennett CL, Fintel D, Grosshans N, Syegco R, Davidson CJ. Post- Cardiac Catheterization Access Site Complications and Low-Molecular-Weight Heparin Following Cardiac Catheterization.  The Journal of Invasive Cardiology, 15 (2): 60-62, 2003.
  183. Arozullah AM, Parada J, Bennett CL, Deloria-Knoll M, Chmiel JS, Phan L, Yarnold PR.  A Rapid Staging System for Predicting Mortality From HIV-Associated Community-Acquired Pneumonia. Chest, 123: 1151-1160, 2003.
  184. Bennett CL, Schumock GT.  Cost Analysis of Adjunct Colony Stimulating Factors for Older Patients with Acute Myeloid Leukaemia.  Drugs & Aging, 20(7):479-483, 2003.
  185. Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL. Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs (2000 to 2002): First Results from the RADAR Project.  Journal of Clinical Oncology, 21(20): 3859-66, 2003.
  186. Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, Demetri GD, Bennett CL. Use of Erythropoietin for cancer patients: Assessment of oncologists’ practice patterns in the United States and other countries.  The American Journal of Medicine, 116:28-34, 2004.
  187. Sureka A, Deloria-Knoll M, Chmiel JS, Phan L, Lyons TM, Ali S, Parada JP, Yarnold PR, Weinstein RA, DeHovitz JA, Jacobson JM, Goetz MB, Campo RE, Berland D, Bennett CL, Uphold CR. HIV- Related Pneumonia Care in Older Patients Hospitalized in the Early HAART Era.  AIDS Patient Care and STDs, 2004 Feb;18(2):99-107.
  188. Uphold CR, Deloria-Knoll M, Palella FJ, Parada JP, Chmiel JS, Phan L, Bennett CL. U.S. Hospital Care for HIV-Infected Persons with Pneumonia and the Role of Public, Private, and Veterans Affairs Hospitals in the Early HAART Era.  Chest, Feb 2004; 125: 548 - 556.
  189. Calhoun EA, Fishman DA, Lurain JR, Welshman EE, Bennett CL. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians.  Gynecological Oncology, 93(1):164-9, 2004.
  190. Calhoun EA, Fishman DA, Lurain JR, Welshman EE, Bennett CL.  A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians.  Gynecologic Oncology, Volume 93, Issue 1, April 2004, Pages 164-16.
  191. Knight SJ, Siston AK, Chmiel JS, Slimack N, Elstein AS, Chapman GB, Nadler RB, Bennett CL. Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans.  Clinical Prostate Cancer, 3(1):31-7, 2004.
  192. Rozovsky J, Parada JP, Phan L, Droller DG, McAuley J, DeHovtiz JA, Jacobson J, Goetz MB,  Campo R, Berland D, Deloria-Knoll M, Weinstein RA, Chmiel JS, Bennett CL. Delays in Suspicion and Tuberculosis Isolation among 937 Persons Hospitalized with Pulmonary TB at Public and Private Hospitals in Chicago, Los Angeles, and Southern Florida during 1996 to 1999. Chest. 01/2005;127(1):205-212.
  193. Parada JP, Deloria-Knoll M, Chmiel JS, Arozullah AM, Phan L, Ali SN, Goetz MB, Weinstein RA, Campo R, Jacobson J, Dehovitz J, Berland D, Bennett CL. Relationship between health insurance and medical care for patients hospitalized with human immunodeficiency virus-related Pneumocystis carinii pneumonia, 1995-1997: Medicaid, bronchoscopy, and survival.  Clinical Infectious Diseases, 37(11):1549-55, 2003.
  194. Patel SM, Johnson S, Belknap SM, Chan J, Sha B, Bennett CL. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV infected individuals.  JAIDS, 35:120- 125, 2004.
  195. Talamonti MS, Kim SP, Yao KA, Wayne JD, Feinglass J, Bennett CL, Rao S.  Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery, 134(4):720-7; discussion 727-9, 2003.
  196. Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch D, Kim B, Kwaan HC, McKoy J, Schmitt B, Davidson C, Yarnold PR, Gorelick P, Bennett CL.  Clopidogrel-Associated TTP: An Update of Pharmacovigilance Efforts Conducted by Independent Researchers, Pharmaceutical Suppliers, and the Food and Drug Administration.  Stroke, 35: 533-37, 2004.
  197. Elstein AS, Chapman GB, Chmiel JS, Knight SJ, Chan C, Nadler RB, Kuzel TM, Siston AK, Bennett CL. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance.  Health Expect. 2004 Jun;7(2):115-25.
  198. Kim SP, Feinglass J, Bennett CL, Lyons T, Simon C, Weinberg MN, Talamonti MS.  Merging Claims Databases with a Tumor Registry to Evaluate Variations in Cancer Mortality: Results from a Pilot Study of 698 Colorectal Cancer Patients Treated at One Hospital in the 1990s.  Cancer Investigation, 22:(2) 225-33, 2004.
  199. Golub RM, Bennett CL, Stinson T, Venta L, Morrow M.  Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms. Journal of Clinical Oncology, 22(12):2430-7, 2004.
  200. Dolan NC, Ferreira MR, Davis TC, Fitzgibbon ML, Rademaker A, Liu D, Schmitt BP, Gorby N, Wolf M, Bennett CL. Colorectal cancer screening knowledge, attitudes, and beliefs among veterans: does literacy make a difference? Journal of Clinical Oncology, 22(13):2617-22, 2004.
  201. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI. American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer. Journal of Clinical Oncology, 22(14):2927-41, 2004.
  202. Arozullah AM, Calhoun EA, Wolf MS, Finley DK, Fitzner KA, Heckinger EA, Gorby NS, Schumock GT, Bennett CL. The Financial Burden of Cancer: Estimates from a Study of Insured Women with Breast Cancer. Journal of Supportive Oncology,2:271–278, 2004.
  203. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio S, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N.  Pure Red-Cell Aplasia and Epoetin Therapy.  New Engl J Med 351(14):1403-8, 2004.
  204. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, Bennett CL. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.  Journal of Clinical Oncology,1;22(17):3524-30, 2004.
  205. Ferreira MR, Dolan NC, Fitzgibbon ML, Davis TC, Gorby N, Ladewski L, Liu D, Rademaker AW, Medio F, Schmitt BP, Bennett CL. A Health Care provider-directed intervention to increase colorectal cancer screening among veterans: results of a randomized controlled trial. Journal of Clinical Oncology, 2005; 23:1548-1554.
  206. Passman RS, Gingold DS, Amar D, Lloyd-Jones D, Bennett CL, Zhang H, Rusch VW.  Prediction rule for atrial fibrillation after major noncardiac thoracic surgery.  Annals of Thoracic Surgery, 79(5):1698-703, 2005.
  207. Pickard AS, Hung SY, McKoy JM, Witt WP, Arseven A, Sharifi R, Wu Z, Knight SJ, McWilliams N, Schumock GT, Bennett CL.  Opportunities for disease state management in prostate cancer. Disease Management, 8(4):235-44, 2005.
  208. Zakarija A, Bennett CL. Low-molecular-weight heparins: do we have the GUSTO to identify differences between alternative formulations?  Archives of Internal Medicine, 165(7):722-3, 2005.
  209. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett CL, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.  Journal of the National Cancer Institute, Apr 6; 97(7):489-98, 2005.
  210. Wolf MS, Rademaker AW, Bennett CL, Ferreira MR, Dolan NC, Davis TC, Medio F, Liu D, Lee J, Fitzgibbon ML. Colon cancer screening knowledge and attitudes among veterans: development of a brief survey.  Preventing Chronic Disease, Epub 2(2):A11, 2005.
  211. Ferreira MR, Dolan NC, Fitzgibbon ML, Newlin R, Davis TC, Rademaker AW, Schmitt BP, Medio  F, Bennett CL. An Intervention to Increase Colorectal Cancer Screening Among Veterans: Rationale and Study Design. International Journal of Cancer Prevention, 2005; 23(7): 1548-1554.
  212. Dolan NC, Ferreira MR, Fitizgibbon ML, Davis TC, Rademaker AW, Liu D, Lee J, Wolf M, Schmitt BP, Bennett CL. Colorectal cancer screening among African-American and white male veterans. American Journal of Preventive Medicine, 28(5):479-82, 2005.
  213. Nebeker JR, Hoffman JM, Bennett CL, Hurdle JF, Weir CR.  High Rates of Adverse Drug Events in a Highly Computerized Hospital.  Archives of Internal Medicine, vol.165(10):1111-6, 2005.
  214. Kramer KM, Bennett CL, Pickard AS, Lyons EA, Wolf MS, McKoy JM, Knight SJ.  Patient preferences in prostate cancer: a clinician's guide to understanding health utilities.  Clinical Prostate Cancer, 4(1):15-23, 2005.
  215. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, Carson KR, Belknap SM, Trifilio SM, Schumock GT, Yarnold PR, Davidson CJ, Evens AM, Kuzel TM, Parada JP, Cournoyer D, West DP, Sartor O, Tallman MS, Raisch DW. The Research on Adverse Drug events And Reports (RADAR) project. JAMA, 293(17) 2131-2140, 2005.
  216. Calhoun EA, Schumock GT, McKoy JM, Pickard S, Fitzner KA, Heckinger EA, Powell EF, McCaffrey KR, Bennett CL.  Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited.  Pharmacoeconomics, 23(8):767-75, 2005.
  217. Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N. Long-term outcome of individuals with pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant epoetin: A follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.  Blood. 2005 Aug 11; [Epub ahead of print]]
  218. Evens AM, Bennett CL, Luminari S. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.  Best Practices & Research Clinical Haematology, 18(3):481-489, 2005.
  219. Bennett CL. The Blue Cross Blue Shield assessment technology review: summary of findings.  Best Practices & Research Clinical Haematology, 18(3):423-31, 2005.
  220. Bohlius JF, Langensiepen S, Engert A, Schwarzer G, Bennett CL. Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Practices & Research Clinical Haematology, 18(3):449-54, 2005.
  221. Carson KR, Evens AM, Bennett CL, Luminari S. Clinical characteristics of erythropoietin- associated pure red cell aplasia. Best Practices & Research Clinical Haematology, 18(3):467-472, 2005.
  222. Wolf MS, Davis TC, Arozullah A, Penn R, Arnold C, Sugar M, Bennett CL.  Relation between literacy and HIV treatment knowledge among patients on HAART regimens.  AIDS Care, 17(7):863- 73, 2005.
  223. Wolf MS, Bennett CL, Davis TC, Marin E, Arnold C. A qualitative study of literacy and patient response to HIV medication adherence questionnaires. J Health Commun. 2005 Sep; 10(6):509-17.
  224. Djulbegovic B, Frohlich A, Bennett CL. Acting on imperfect evidence: How much regret are we ready to accept? J Clin Oncol. 2005 Oct 1; 23(28):6822-5. Epub 2005 Sep 6.
  225. Nebeker JR, Bennett CL. Reducing adverse drug events in the outpatient chemotherapy setting: attention must be paid. Cancer. 2005 Dec 1;104(11):2289-91.
  226. Wolf MS, Fitzner KA, Powell EF, McCaffrey KR, Pickard AS, McKoy JM, Lindenberg J, Schumock GT, Carson KR, Ferreira MR, Dolan NC, Bennett CL. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. J Clin Oncol. 2005 Dec 1;23(34):8877-83.
  227. McKoy JM, Lyons EA, Obadina E, Carson K, Pickard AS, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor O, Schumock GT, McCaffery K, Bennett CL Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J Clin Oncol. 2005 Dec 1;23(34):8894-905.
  228. Kwaan HC, Bennett CL Thrombotic thrombocytopenic purpura-2005. Semin Thromb Hemost. 2005 Dec;31(6):611-4.
  229. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005 Dec;31(6):681-90.
  230. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006 Jan 3;47(1):175-81.
  231. Wolf MS, Bennett CL Local perspective of the impact of the HIPAA privacy rule on research. Cancer. 2006 Jan 15;106(2):474-9.
  232. Belknap SM, Kuzel TM, Yarnold PR, Slimack N, Lyons EA, Raisch DW, Bennett CL. Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer. 2006 May 1;106(9):2051-7.
  233. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May 17;98(10):708-14.
  234. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 1;24(19):3187-205.
  235. Adams JR, Angelotta C, Bennett CL. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?J Clin Oncol. 2006 Jul 1;24(19):2975-7. Epub 2006 May 8.
  236. Wolf MS, Knight SJ, Lyons EA, Durazo-Arvizu R, Pickard SA, Arseven A, Arozullah A, Colella K, Ray P, Bennett CL. Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer. Urology. 2006 Jul;68(1):89-93.
  237. Davis TC, Wolf MS, Bass PF 3rd, Middlebrooks M, Kennen E, Baker DW, Bennett CL, Durazo- Arvizu R, Bocchini A, Savory S, Parker RM. Low literacy impairs comprehension of prescription drug warning labels. J Gen Intern Med. 2006 Aug 2;1(8):847-51.
  238. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, Deangelo DJ, Giles FJ. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007 May; 31(5): 599-604. Epub 2006 Sep 7.
  239. Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Jahanzeb M, Leung LL, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB. Venous thromboembolic disease. J Natl Compr Canc Netw. 2006 Oct;4(9):838-69.
  240. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006 Oct 19;135(5): 642-50.
  241. Bennett CL, Angelotta C., Yarnold PR, Evens AM, Zonder AM, Raisch DW, Richardson P. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.  JAMA 2006 Dec 6;296(21):2558-60.
  242. Wolf MS, Davis TC, Osborn CY, Skripkauskas S, Bennett CL, Makoul G. Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns. 2007 Feb;65(2):253-60.
  243. Kyriacou DN, Yarnold PR, Stein AC, Schmitt BP, Soltysik RC, Nelson RR, Frerichs RR, Noskin GA, Belknap SM, Bennett CL. Discriminating inhalational anthrax from community-acquired pneumonia using chest radiograph findings and a clinical algorithm. Chest. 2007 Feb;131(2):489-96.
  244. Hershman D, Neugat AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony- stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007 Feb 7;99(3):196-205.
  245. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, Kontoyiannis DP. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.  Bone Marrow Transplant. 2007 Feb 19.
  246. Angelotta C, Bennett CL. Adverse events alert: Thalidomide-and lenalidomide-associated thromboembolism. Community Oncology. March 2007; 4:147-148.
  247. Lagman JL, Tigue CC, Trifilio SM, Belknap S, Buffie CG, and Bennett CL. 2007. Community Oncology volume 4, number 1. pp. 45-46.
  248. Tigue CC and Bennett CL. Counterfeit epoetin alfa products. 2007. Community Oncology volume 3, number 12. pp. 772-773.
  249. Bennett CL, Tigue CC, Angelotta C, McKoy JM, Edwards BJ. Adverse effects of drugs used to treat hematologic malignancies: Surveillance efforts from the Research on Adverse Drug Events and Reports project. Seminars in Thrombosis and Hemostasis 2007;33(4):365-72.
  250. Tigue CC, Fitzner KA, Alkhatib M, Schmid E, Bennett CL. The value of innovation: The economics of targeted drugs for cancer. Targ Oncology (2007) 2: 113-119.
  251. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients. Oncologist. Apr 2007; 12(4): 478-483.
  252. Evens AM, Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A, Miyata S, Catsaros K, Augustyniak C, Bennett CL, Tallman MS, Variakojis D, Winter JN, Gordon LI.  G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin Lymphoma: Low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol.  2007 Apr; 137:545-552.
  253. Bennett CL, Nebecker JR, Yarnold PR, et al. Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs  Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med 2007;167(10):1041-9.
  254. McKoy JM, Fitzner KA, Edwards BJ, Alkhatib M, Tigue CC, Nonzee NJ, Bolden CR, and Bennett CL. Cost considerations in the management of cancer in the older patient. Oncology June 2007; 21(7): 851-857.
  255. Bennett CL, Kim B, Zakarija A, Bandarenko N, Pandey Dk, Buffie CG, McKoy JM, Tevar AD, Cursio JF, Yarnold PR, Kwaan HC, DeMasi D, Sarode R, Raife TJ, Kiss JE, Raisch DW, Davidson C, Sadler JE, Ortel TL, Zheng XL, Kato S, Matsumoto M, Uemura M, Fujimura Y; SERF-TTP Research Group. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007 Sep 18;50 (12) : 1138-43.
  256. Shankaran V, McKoy JM, Dandade N, Nonzee NJ, Tigue CC, Bennett CL, Denberg TD. Costs and cost-effectiveness of a low intensity patient-directed intervention to promote colorectal cancer screening. J Clin Oncol. November 2007; 25(33): 5248-53.
  257. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associate anemia. JAMA 2008; 299 (8): 914- 924.
  258. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008 Dec;9(12):1166-72.
  259. Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Hutchinson S, Jahanzeb M, Lee J, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB, Vedantham S; National Comprehensive Cancer Network.Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008 Sep;6(8):716-53.
  260. Nickel JC, Alexander RB, Anderson R, Berger R, Comiter CV, Datta NS, Fowler JE, Krieger JN, Landis JR, Litwin MS, McNaughton-Collins M, O'Leary MP, Pontari MA, Schaeffer AJ, Shoskes  DA, White P, Kusek J, Nyberg L; Chronic Prostatitis Collaborative Research Network Study Groups. Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies. Curr Urol Rep. 2008 Jul;9(4):320-7.
  261. Rodgers GM 3rd, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Djulbegovic B, Garst JL, Gilreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vij R; National Comprehensive Cancer Network. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008 Jul;6(6):536-64.
  262. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008 Aug;48(8):1754-62. Epub 2008 May 14.
  263. Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med. 2008 Mar 24;168(6):632-42.
  264. McKoy JM, Tigue CC, Bennett CL. Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin. Cancer Treat Res. 2008;140:235-51.
  265. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE; American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 1;26(1):132-49. Epub 2007 Oct 22. Erratum in: J Clin Oncol. 2008 Mar 1;26(7):1192.
  266. Massenburg RD, Feinglass J, Bennett CL. Non-Hodgkins lymphoma: how well you do may depend on where you live. Leuk Lymphoma. 2008 May;49(5):841-2.
  267. Wells KJ, Battaglia TA, Dudley DJ, Garcia R, Greene A, Calhoun E, Mandelblatt JS, Paskett ED, Raich PC; Patient Navigation Research Program. Patient navigation: state of the art or is it science? Cancer. 2008 Oct 15;113(8):1999-2010.
  268. Freund KM, Battaglia TA, Calhoun E, Dudley DJ, Fiscella K, Paskett E, Raich PC, Roetzheim RG; The Patient Navigation Research Program Group. National Cancer Institute Patient Navigation Research Program : methods, protocol, and measures. Cancer. 2008 Dec 15;113(12):3391-3399.
  269. Samaras AT and Bennett CL. Risks of venous thromboembolism and mortality associated with erythropoietin stimulating agents for the treatment of cancer-associated anemia. Am J Hem/Onc. Aug 2008; 7(8):327-332.
  270. Bennett CL, Becker PS, Kraut EH, Samaras AT and West DP. Intersecting Guidelines: Administering Erythropoiesis-Stimulating Agents to Chronic Kidney Disease Patients with Cancer. Semin Dial. 2009 Jan-Feb; 22(1): 1-4. Epub 2008 Dec 5.
  271. Nonzee NJ, Dandade NA, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, Bennett CL. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer  care center. Cancer. 2008 Sep 15;113(6):1446-52.
  272. Bennett CL, Lawson VH, Brickell KL, Isaacs K, Seltzer W, Lipe HP, Weiss MD, Carter GT, Flanigan KM, Chance PF, Bird TD. Late-onset hereditary axonal neuropathies. Neurology. 2008 Jul 1;71(1):14-20. Epub 2008 May 21
  273. Bennett CL, Petros TV, Johnson M, Ferraro FR. Individual differences in the influence of time of day on executive functions. Am J Psychol. 2008 Fall;121(3):349-61.
  274. Wideroff L, Phillips KA, Randhawa G, Ambs A, Armstrong K, Bennett CL, Brown ML, Donaldson MS, Follen M, Goldie SJ, Hiatt RA, Khoury MJ, Lewis G, McLeod HL, Piper M, Powell I, Schrag D, Schulman KA, Scott J. A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics. 2009;12(4):233-44. Epub 2009 Feb 20. Review
  275. McKoy JM, Bennett CL, Scheetz MH, Differding V, Chandler KL, Scarsi KK, Yarnold PR, Sutton  S, Palella F, Johnson S, Obadina E, Raisch DW, Parada JP. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf. 2009;32(2):147-58. doi: 10.2165/00002018-200932020-00007.
  276. Irizarry LD, Luu TH, McKoy JM, Samaras AT, Fisher MJ, Carias EE, Raisch DW, Calhoun EA, Bennett CL. Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action. 2009. Community Oncology Volume 6, number 3. Pp. 132-134.
  277. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009 Jan;249(1):63-71.
  278. Pickard AS, Lin HW, Knight SJ, Sharifi R, Wu Z, Hung SY, Witt WP, Chang CH, Bennett CL. Proxy assessment of health-related quality of life in African American and white respondents with prostate cancer: perspective matters. Med Care. 2009 Feb;47(2):176-83. Erratum in: Med Care. 2009 Apr;47(4):491. Knight, Sara L
  279. Zakarija A, Kwaan HC, Moake JL, Bandarenko N, Pandey DK, McKoy JM, Yarnold PR, Raisch  DW, Winters JL, Raife TJ, Cursio JF, Luu TH, Richey EA, Fisher MJ, Ortel TL, Tallman MS, Zheng XL, Matsumoto M, Fujimura Y, Bennett CL. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl. 2009 Feb;(112):S20-4. Review.
  280. Carson KR, Bennett CL. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma. 2009 Mar;50(3):323-4.
  281. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer   GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a  report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14;113(20):4834-40. Epub 2009 Mar 5
  282. Simon MA, Dong X, Nonzee N, Bennett CL. Heeding our words: complexities of research among low-literacy populations. J Clin Oncol. 2009 Apr 20;27(12):1938-40. Epub 2009 Mar 23.
  283. Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun 1;15(11):3850-5. Epub 2009 May 19.
  284. McKoy JM, Samaras AT, Bennett CL. Providing cancer care to a graying and diverse cancer population in the 21st century: are we prepared? J Clin Oncol. 2009 Jun 10;27(17):2745-6. Epub 2009 Apr 29.
  285. Simon MA, Dong X, Bennett CL. Partnering to promote equality in cancer care. Soc Work Public Health. 2009 Jul-Aug;24(4):355-9.
  286. McKoy JM, Samaras AT, Luu TH, Bennett CL. Upping recruitment in clinical trials: are the costs worth it? Onkologie. 2009 Jul;32(7):378-9. Epub 2009 Jun 20.
  287. O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes- Rovner M, Khangura S, Llewellyn-Thomas H, Rovner D. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001431.
  288. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009 Aug;10(8):816-24.
  289. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, Nonzee N, Trifilio S, Sartor O, Benson AB 3rd, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10;27(26):4398-405. Epub 2009 Jul 27.
  290. Ramsey S, Whitley E, Mears VW, McKoy JM, Everhart RM, Caswell RJ, Fiscella K, Hurd TC, Battaglia T, Mandelblatt J; Patient Navigation Research Program Group. Evaluating the cost- effectiveness of cancer patient navigation programs: conceptual and practical issues. Cancer. 2009 Dec 1;115(23):5394-403.
  291. Shankaran V, Luu TH, Nonzee N, Richey E, McKoy JM, Graff Zivin J, Ashford A, Lantigua R, Frucht H, Scoppettone M, Bennett CL, Sheinfeld Gorin S. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening. J Clin Oncol. 2009 Nov 10;27(32):5370-5. Epub 2009 Oct 13.
  292. Mayhew R, McKoy JM, Ha Luu T, Lopez I, Frick M, Bennett CL. Adverse drug interactions: moving from perception to action. Pharmacoeconomics. 2010;28(1):19-22.
  293. Antonova P, Jacobs DI, Bojar M, Cerny R, Ciharova K, Frick MA, Fintel B, DeHovitz J, Bennett CL. Czech health two decades on from the Velvet Revolution. Lancet. 2010 Jan 16; 375(9710):179- 81.
  294. Scandrett KG, Reitschuler-Cross EB, Nelson L, Sanger JA, Feigon M, Boyd E, Chang CH, Paice JA, Hauser JM, Chamkin A, Balfour P, Stolbunov A, Bennett CL, Emanuel LL. Feasibility and effectiveness of the NEST13+ as a screening tool for advanced illness care needs. J Palliat Med.  2010 Feb;13(2):161-9.
  295. Parada JP, Yarnold PR, Uphold CR, Chmiel JS, DeHovitz JA, Goetz MB, Weinstein RA, McKoy JM, Chandler KL, Bennett CL. Racial variations in care and outcomes for inpatient HIV-related pneumocystis pneumonia. J Health Care Poor Underserved. 2010 Feb;21(1):318-33.
  296. Bennett CL, Adegboro OS, Calhoun EA, Raisch D. Beyond the black box: drug-and device- associated hypersensitivity events. Drug Healthc Patient Saf. 2010; 2:1-5. Epub 2010 Feb 16.
  297. Bennett CL, McKoy JM, Henke M, Silver SM, MacDougall IC, Birgegård G, Luminari S, Casadevall N, Schellekens H, Sartor O, Lai SY, Armitage JO. Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park). 2010 Mar;24(3):260-8.
  298. Steadman E, Raisch DW, Bennett CL, Esterly JS, Becker T, Postelnick M, McKoy JM, Trifilio S, Yarnold PR, Scheetz MH. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother. 2010 Apr;54(4):1534-40. Epub 2010 Jan 19.
  299. Bennett CL, Burke SE, Burton H, Farndon PA. A toolkit for incorporating genetics into mainstream medical services: Learning from service development pilots in England. BMC Health Serv Res. 2010 May 14;10:125.
  300. Hynes DM, Tarlov E, Durazo-Arvizu R, Perrin R, Zhang Q, Weichle T, Ferreira MR, Lee T, Benson AB, Bhoopalam N, Bennett CL. Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study.  JCO 2010 May 20;28 (15):2571-76.
  301. Ray PS, Bennett CL. Editorial comment. Urology. 2010 Aug;76(2):401-2.
  302. Norris LB, Qureshi ZP, Bookstaver PB, Raisch DW, Sartor O, Chen H, Chen F, Bennett CL. Polysorbate 80 hypersensitivity reactions: a renewed call to action. 2010. Community Oncology volume 7, number 9. pp. 425-428.
  303. Hemani ML, Bennett CL. The excessive cost of early stage bladder cancer care: are providers really to blame? Cancer. 2010 Aug 1;116(15):3530-2.
  304. Ablin RJ, Sartor O, Bennett CL. Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".Arch Intern Med. 2010 Aug 9;170(15):1397-9.
  305. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, Bennett CL, Kwaan HC. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010 Sep;95(9):1555-62. Epub 2010 Apr 7.
  306. Bennett CL, Lai SY, Henke M, Barnato SE, Armitage JO, Sartor O. Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med. 2010 Sep 13;170(16):1490-8.
  307. Miller AD, Piro CC, Rudisill CN, Bookstaver PB, Bair JD, Bennett CL. Nighttime and weekend medication error rates in an inpatient pediatric population. Ann Pharmacother. 2010 Nov;44(11):1739-46. Epub 2010 Oct 19.
  308. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH Somerfield MR. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darboepoetin in adult patients with cancer. Blood.2010 Nov 18; 116(20):4045-59.Epub 2010 Oct 25.
  309. Xirasagar S, Bennett CL, Hebert JR. Screening colonoscopy vs flexible sigmoidoscopy. JAMA 2010 Nov 10; 304(18):2016-7; author reply 2017-8.
  310. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH Somerfield MR. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darboepoetin in adult patients with cancer. J Clin Oncol. 2010 Nov 20; 28(33)4996-5010. Epub 2010 Oct 25.
  311. Qureshi ZP, Sartor O, Bennett CL. Radiation overexposure following brain perfusion CT scans in California , Florida, and Alabama (2008-2009). 2011. Community Oncology volume 8, number2. pp 89-91.
  312. Trenery A, Qureshi ZP, Rowen R, Day T, Norris LB, Bennett CL. First Bite Syndro-me: An interesting complication of carotid body paraglioma resection. Community Oncology, 2011;8(8):375- 8.
  313. Rudisill C, Qureshi ZP, Armstrong JM, Norris LB, Bennett CL. A probable serotonin syndrome complicating a routine screening colonoscopy procedure. Community Oncology. 2011; 8(1):41-42.
  314. Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, Samaras AT, Boyle SN, Bennett CL, West DP, Guise TA. Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer. Clin Cancer Res. 2011; 17:560-8.
  315. Miller AD, Ball AM, Bookstaver BB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates and clinical consideration. Pharmacotherapy. 2011 Apr; 31(4): 408-423.
  316. Qureshi ZP, Liu Y, Sartor O, Chu YH, Bennett CL. Enformcement actions involving Medicaid fraud and abuse, 1996-2009. Arch Intern Med , 2011 Apr 25; 171(8): 785-7.
  317. Felder TM, Lal LS, Bennett CL, Hung F, Franzini L. Cancer patients' use of pharmaceutical patient assistance programs in the outpatient pharmacy of a large tertiary cancer center. Community Oncology. 2011 June; 8 (6): 279-286.
  318. Raisch DW, Campbell W, Garg V, Qureshi ZP, Bookstaver PB, Norris LB, Bennett CL. Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf, 2011 Jul; 10(4): 521-8. Epub 2011 May 20.
  319. Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D’Amico AV. Cardiovascular comorbidity and treatment regret in men with recurrent  prostate cancer. BJU International, 2012 Jul; 110(2): 201-205.
  320. Qureshi ZP, Sartor O, Xirasagar S, Liu Y, Bennett CL. Pharmaceutical fraud and abuse in the United States, 1996-2010. Arch Intern Med 2011 Sep 12; 171(16):1503-6.
  321. Qureshi ZP, Norris LB, Sartor O, McKoy JM, Armstrong J, Raisch DW, Garg V, Stafkey-Mailey D, Bennett CL. Caveat Oncologist: Clinical Findings and Consequences of Distributing Counterfeit Erythropoietin in the United States. Journal of Oncology Practice.2012 Mar 1;8(2):84-90. published ahead of print December 13, 2011
  322. Matsumoto M, Bennett CL, Isonishi A, Qureshi ZP, Hori Y, Hayakawa M, Yoshida Y, Yagi H, Fujimura Y. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS ONE, 2012; 7(3): e33029.
  323. Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor AO, Lai SY, Tallman MS, Raisch D, Weiss Smith S, Silver S, Murday AS, Schellekens H, Casadevall N, Armitage JO, Goldsmith D. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis & Hemostasis. 2012; 38(8): 783-796.
  324. Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, McKoy JM, Barnato SE, Winters JL, Cursio JF, Weiss I, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Rock G, Matsumoto M, Fujimura Y, Zheng XL, Chen HJ, Chen F, Armstrong JM, Raisch DW, Bennett CL. Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A Twenty–Year Review. A report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis & Hemostasis. 2012; 38: 845-853.
  325. Maxwell W, Bennett CL. Venous Thromboembolism: a Review of Burden, Risk Factors, and Evidence in Support of Thromboprophylaxis in Ambulatory Cancer Patients Receiving Chemotherapy. A report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis & Hemostasis. 2012; 38: 759-767.
  326. Moore TJ, Bennett CL. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: Empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide. A report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis & Hemostasis. 2012; 38: 905-907.
  327. Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor AO, MacDougall I, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye’s syndrome. A report from the SOuthern Network on Adverse Reactions (SONAR). J  Genl Intern  Med, 2012 Dec;27(12):1697-703. doi: 10.1007/s11606-012-2098-1. Epub 2012 Jun 13.
  328. Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium Induced Nephrogrenic Systemic Fibrosis, the Rise and Fall of an Iatrogenic Disease. Clinical Kidney Journal,  2012; 5: 82-88.
  329. Bennett CL. A 56-year-old physician who underwent a PSA test. Arch Intern Med, 2012 Feb 27; 172(4):311.
  330. Bennett CL. Pharmacovigilance and PML in the oncology setting. Cleve Clin J Med, 2011; 78 Suppl 2: S13-7.
  331. Bian J, Bennett C, Fisher D, Ribeiro M, Lipscomb J. Unintended consequences of health information technology: evidence from Veterans Affairs Colorectal Cancer Oncology Watch intervention. J Clin Oncol, 2012 Nov 10;30(32):3947-52. doi: 10.1200/JCO.2011.39.7448. Epub 2012 Oct 8.
  332. Chen B, Restaino J, Norris LB, Xirasagar S, Qureshi ZP, McKoy JM, Lopez I, Trenery A, Murday A, Kahn A, Mattison DR, Ray P, Sartor AO, Bennett CL. A tale of two citizens: a state attorney general and a hematologist facilitate translation of research into FDA actions. J Oncol Practice 2012. doi: 10.1200/JOP.2011.000504
  333. Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor AO, Lai SY, Tallman MS, Raisch D, Weiss Smith S, Silver S, Murday AS, Schellekens H, Casadevall N, Armitage JO, Goldsmith D. A review of safety, efficacy, and utilization of eythropoiesis stimulating agents (ESAs) for patients with cancer or chronic kidney disease: A report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis & Hemostasis. 2012; 38: 783-796.
  334. Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, McKoy JM, Barnato SE, Winters JL, Cursio JF, Weiss I, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Rock G, Matsumoto M, Fujimura Y, Zheng XL, Chen HJ, Chen F, Armstrong JM, Raisch DW, Bennett CL. Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A Twenty–Year Review. A report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis & Hemostasis. 2012; 38: 845-853.
  335. Maxwell W, Bennett CL. Venous Thromboembolism: a Review of Burden, Risk Factors, and Evidence in Support of Thromboprophylaxis in Ambulatory Cancer Patients Receiving Chemotherapy. A report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis & Hemostasis. 2012; 38: 759-767.
  336. Moore TJ, Bennett CL. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: Empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide. A report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis & Hemostasis. 2012; 38: 905-907.
  337. Kwaan HC, Bennett CL. Adverse effects of drugs on hemostasis and thrombosis. Seminars in Thrombosis & Hemostasis. 2012; 38: 755-758.
  338. Maxwell W, Bennett CL. Will newer anticoagulants improve therapy persistence? Comment on “Persistence with therapy among patients treated with warfarin for atrial fibrillation”. Archives of Internal Medicine. 2012 Oct 22; 172(21): 1689-1690.
  339. Cunningham JE, Walters CA, Hill EG, Ford ME, Barker-Elamin T, Bennett CL. Mind the gap: racial differences in breast cancer incidence and biologic phenotype, but not stage, among low-income women participating in a government-funded screening program. Breast Cancer Research Treatment. 2013 Jan;137(2):589-98. doi: 10.1007/s10549-012-2305-0. Epub 2012 Dec 13.
  340. Li Y, Xirasagar X,  Pumkam C, Krisjnaswamy M, Bennett CL. Vision insurance, eye care visits, and vision impairment among working-age adults in the United States. JAMA Opthalmol; 2013 Apr;131(4):499-506.
  341. Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen depreivation, or radiation therapy alone. Urology. 2013; 81(1): 130-135.
  342. Sutton SS, Stacy JJ, Mensch J, Torres-McGehee T, Bennett CL. Tackling community-acquired methicillin-resistant Staphylococcus aurues (CA-MRSA) in collegiate football players following implementation of an anti-MRSA programme and has been revised after receiving peer review information. British Journal of Sports Medicine. 2013 Feb. [E-pub ahead of print].
  343. Bennett CL, Jacob S, Dunn BL, Georgantopoulos P, Zheng XL, Kwaan HC, McKoy JM, Magwood JS, Qureshi ZP, Bandarenko N, Winters JL, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Ablin RJ, Rock G, Matsumoto M, Fujimura Y. Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). British Journal of Haematology. 2013 Jun;161(6):896-8. doi: 10.1111/bjh.12303. Epub 2013 Mar 27.
  344. Rao GA, Joshua R Mann JR, Azza Shoaibi A, Pai SG, Bottai M, Sutton SS, Haddock KS, Bennett CL, Hebert J. Angiotensin receptor blockers: are they related to lung cancer? J Hypertens. April 2013; 31: 1669-1675.
  345. Bennett CL, Djulbegovic B, Norris L, Armitage J. Colony-Stimulating factors for febrile neutropenia during cancer therapy. New Engl J Med. 2013; 368(12):1131-9.
  346. Victorson DE, Brucker PS, Bode RK, Eton DT, Talcott JA, Clark JA, Knight SJ, Litwin MS, Moinpour CM, Reeve BB, Aaronson NK,
  347. Bennett CL, Herr HW, McGuire M, Shevrin D, McVary K, Cella D. Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan;32(1):26.e25-31. doi: 10.1016/j.urolonc.2012.09.006. Epub 2013 Mar 21.
  348. Rao GA, Mann JR, Bottai M, Uemura H, Burch JB, Bennett CL, Haddock KS, Hébert JR. Angiotensin Receptor Blockers and Risk of Prostate Cancer Among United States Veterans. J Clin Pharmacol. 2013 Jul;53(7):773-8. doi: 10.1002/jcph.98. Epub 2013 May 17.
  349. Li YJ, Xirasagar S, Pumkam C, Krishnaswamy M, Bennett CL. Vision insurance, eye care visits, and vision impairment among working-age adults in the United States. JAMA Ophthalmology. 2013 Apr;131(4):499-506.
  350. Magwood JS, Murday AS, Zhu NY, Georgantopoulos  P, Qureshi ZP, Buchanan JA, Baumbach J, Dy IA,  Norris L, Dart RC, Gilbert E, Mahindra P, Kehr HA, Rossi AM, Singh S, Edlin BR, Gonsky J,   ay P, Michels J , Richardson W, Garg V, Shen X, Raisch DW, McKoy JM, Rao GA , Sartor O, Ablin RJ, Bennett CL,  Peter H. Wiernik. Levamisole contamination of cocaine resulting in neutropenia and thrombovasculopathy: A report from the Southern Network on Adverse Reactions (SONAR). Commun Oncol 2013;10:364-367. DOI: 10.12788/j.cmonc.0035.
  351. Strassels SA, Dickson M, Norris LB, Bennett CL. Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. Journal of the National Cancer Institute. 2013 Aug 7;105(15):1072-3. doi: 10.1093/jnci/djt198. Epub 2013 Jul 19.
  352. Qureshi ZP, Magwood JS, Singh S, Bennett, CL. Rituximab and Biosimilars – equivalence and reciprocity. Biosimilars 2013:3 19–25.
  353. Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP.  BJU Int. 2013 Sep;112(5):548- 60. doi: 10.1111/bju.12061. Epub 2013 Jul 4. Review.
  354. Felder TM, Bennett CL. Can Patients Afford to Be Adherent to Expensive Oral Cancer Drugs?: Unintended Consequences of Pharmaceutical Development. J Oncology Prac.November 2013 vol. 9 no. 6S 64s-66s. Published online before print September 17, 2013, doi: 10.1200/JOP.2013.001167
  355. Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, Jacob S, Strayer, S. Azithromycin and Levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014 Mar- Apr;12(2):121-7. doi: 10.1370/afm.1601
  356. Hamed S, Bennett CL, Demiot C, Ullmann Y, Teot L, Desmoulière A. Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus. Wound Repair Regen. 2014 Jan-Feb;22(1):23-33. doi: 10.1111/wrr.12135. Epub 2013 Dec 13.
  357. Magwood JS, Lebby A, Chen B, Kessler S, Norris L, Bennett CL. Emerging drugs for treatment of anemia chronic kidney disease. Expert Opin Emerg Drugs. 2013 Dec;18(4):421-9. doi: 10.1517/14728214.2013.836490. Epub 2013 Sep 16.
  358. Davis TC, Arnold CL, Bennett CL, Wolf MC, Reynolds C, Liu D, Rademaker A. Strategies to Improve Repeat Fecal Occult Blood Testing Cancer Screening. Cancer Epidemiol Biomarkers Prev 2014 Jan;23(1):134-43. doi: 10.1158/1055-9965.EPI-13-0795. Epub 2013 Nov 5.
  359. Kessler SJ, Bennett CL. Forewarned is forearmed: erythropoietin use in CKD patients with cancer. J Nephrol. 2013 Sep-Oct;26(5):805-6. doi: 10.5301/jn.5000334. Epub 2013 Sep 12.
  360. Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL.Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.  Cancer. 2014 Aug 15;120(16):2464-71. doi: 10.1002/cncr.28712. Epub 2014 Apr 25.
  361. Maxwell WD, Jacob M, Spiryda LB, Bennett CL. Selection of contraceptive therapy for patients with thrombophilia: a review of the evidence. J Womens Health. 2014 Apr;23(4):318-26. doi: 10.1089/jwh.2013.4479. Epub 2014 Feb 19.
  362. Lu ZK, Kessler, SJ, Schulz R, Bian J, Chen B, Wu J, Noxon V, Rao G, Leibnitz R, Restaino J, Fayad R, Jacob S, Georgantopoulos P, Sartor O, Yarnold PR, Huff D, Hrushesky WJM, Raisch DW, Ablin R, Bennett CL. Systemic approach to pharmacovigilance beyond the limits: The Southern Network on Adverse Reactions (SONAR) projects. Adv Pharmacoepidem Drug Safety 2014; 3:149. doi: 10.4172/2167-1052.1000149.
  363. Davis TC, Rademaker A, Bennett CL, Wolf MS, Carias E, Reynolds C, Liu D, Arnold CL. Improving mammography screening among the medically underserved. J Gen Intern Med. 2014 Apr;29(4):628-35. doi: 10.1007/s11606-013-2743-3. Epub 2013 Dec 24.
  364. Bennett CL, Jacob S, Hymes J, Usvyat LA, Maddux FW. Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. 2014 May 22;370(21):2055-6. doi: 10.1056/NEJMc1400883.
  365. Bennett CL, Bian J. Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers.   Br J Cancer. 2014 Jul 29;111(3):421-312.
  366. Bennett CL, Chen B, Wyatt M, Schulz R, Kessler S, Raisch D, Qureshi Z, Lu K, Love B, Norris LeAnn, Georgantopoulos P, Noxon V, Bobbett L, Armitage M, Bian J, Leibnitz R, Ray P, Ablin R, Restaino J, Hrushesky WJM, Macdougall IC, Sartor OA, Armitage J. Biosimilar drugs in oncology: Will they bend the cost curve? Lancet Oncology, In press.
  367. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Bennett CL, Wootton T, Rumble RB, Dusetzina SB, and Virgo KS.  Systemic Therapy in Men With Metastatic Castration- Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline.  J Clin Oncol 10.1200/JCO.2013.54.8404.

Letters to the Editor

  1. Bennett CL, Weinberg PD, Green D. Letter to the Editor (in response to letter submitted by Kenneth J. Mukamal and Barry Wu regarding Ticlopidine associated TTP).  Annals of Internal Medicine. 129(10): 837, 1998.
  2. Bennett CL, Schwartz D, Lane DR, Sipler AM, Bhattacharya M, Kozloff M, Berland D, Pitrak D, Moswin A, Luskin-Hawk R, Weinstein RA.  Variations in inpatient care for HIV-related tuberculosis patients during a recent nosocomial outbreak of multidrug-resistant tuberculosis.  J AIDS.  21(4): 348-9, 1999.
  3. Bennett CL, Davidson CJ, Green D, Weinberg PD, Feldman MD.  Ticlopidine and TTP after coronary stenting. JAMA.  282(18): 1717, 1999.
  4. Scullion B, Knox K, Bennett CL. Quality improvement: carrots or sticks?  J Clin Oncol. 17(12): 3856-60, 1999.
  5. Bennett CL, Somerfield MR. Impact of American Society of Clinical Oncology guidelines for clinical use of colony-stimulating factors. J Clin Oncol 17 (2): 3360-3361, 1999.
  6. Bennett CL, Hounshell JB, Chmiel JS.  Hospital measures for prevention of tuberculosis transmission in US cities with and without previous nosocomial tuberculosis outbreaks.  Annals of Internal Medicine.  133(6): 486, 2000.
  7. Bennett, CL, Connors JM, Moake JL. Clopidogrel and thrombotic thrombocytopenic purpura. (response letter) New Engl J Med. 343(16): 1191-1194, 19, 2000.
  8. Bennett CL, Sipler AM, Parada JP, Goetz MB, DeHovitz JA, Weinstein RA.  Variations in institutional review board decisions for HIV quality of care studies: a potential source of study basis. Journal of Acquired Immune Deficiency Syndromes.  26 (4): 390-1, 2001.
  9. Tigue CC, Trifilio SM, Tallman MS, Goldman JM, Bennett CL. Long-term safety of filgrastim (rhG-CSF) administration: response to Confer & Miller and Bacher & Zander. British Journal of Haematology 137, 79-80.
  10. Prasad SM, Bennett CL. Letter to the editor. Urology. 2013 Jul;82(1):66. doi: 10.1016/j.urology.2013.01.073. Epub 2013 May 21. No abstract available.
  11. Prasad SM, Bennett CL. Finishing the picture: problems with public reporting of clinical trials. J Clin Oncol. 2013 Aug 20;31(24):2981-2. doi: 10.1200/JCO.2013.49.7339. Epub 2013 Jul 22.
  12. Prasad SM, Sartor O, Bennett CL.  Reply to W. Read. J Clin Oncol. 2014 Feb 20;32(6):604-5. doi: 10.1200/JCO.2013.53.7225. Epub 2014 Jan 6. No abstract available
  13. Prasad SM, Sartor O, Bennett CL. Editorial comment.  Urology. 2014 Apr;83(4):786-7. doi: 10.1016/j.urology.2013.11.041. No abstract available.
  14. Djulbegovic B, Norris LB, Bennett CL.Colony-stimulating factors for febrile neutropenia.  N Engl J Med. 2013 Jul 18;369(3):286. doi: 10.1056/NEJMc1306109.
  15. Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21;368(12):1131-9. doi: 10.1056/NEJMct1210890.
  16. Prasad SM, Sartor AO, Bennett CL.  Editorial comment.  Urology. 2014 Jan;83(1):152-3; discussion 153. doi: 10.1016/j.urology.2013.08.085. Epub 2013 Nov 12. No abstract available.

Books

  • Bennett CL and Stinson TJ: Cancer policy: research and methods.  Kluwer Academic Publishers, Boston, 1998.

Book Chapters

  1. Bennett CL, Hillner BE, Smith TJ.  Economic analysis of cancer treatment.  In Abeloff, M., Armitage, J.O., Lichter, A.S., Niederhuber, J.E.: Clinical Oncology. Churchhill Livingstone, New York, pp. 187-00, 1995.
  2. Bennett CL, Gulati SC, Smith TJ, Armitage JL.  A Health Policy Perspective on High-Dose Cancer Therapy: Cost, Effectiveness, and Cost-Effectiveness.  In Armitage JO, Antman KH: High-Dose Cancer Therapy.  Williams and Wilkins, Baltimore, pp. 131-50, 1995.
  3. Westerman IL, Bennett CL. Costs of care for bone marrow transplantations for malignant hematopoietic diseases.  In Burt RK, Deeg HJ, Santo GW: On Call in Bone Marrow Transplantation. Landes, Georgetown, pp. 49-62, 1996.
  4. Bennett CL, Bishop MR, Gulati SC. Economic implications of high dose chemotherapy programs with autologous stem cell support. In Abraham NG, et al.: Molecular Biology of Hematopoiesis, Vol. Plenum Press, New York, pp. 45-52, 1996.
  5. Bennett CL and Stinson TJ. Economic, public health, and policy implications of hematopoietic growth factors, high-dose chemotherapy, and stem cell rescue.  In Wingard JR (Ed): Clinical Applications of Cytokines and Growth Factors.  Kluwer Academic Publishers, Boston, 1998.
  6. Bennett CL, Hillner BE, Smith TJ.  Economic analysis of cancer treatment. In Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds.): Clinical Oncology. 2nd Ed.  Churchill Livingstone, New York, 1998.
  7. Bennett CL and Stinson TJ. A Health Policy Perspective on High Dose Cancer Therapy: Cost, Effectiveness and Cost-Effectiveness.  In Armitage JO and Antman KH (eds.): High Dose Cancer Therapy: Pharmacology, Hematopoietins, and Stem Cells. 3rd Ed. Williams & Wilkins, Baltimore, 1998.
  8. Bennett CL, Tigue CA, Fitzner KA. The Economics of Brain Metastases. In Raizer JJ and Abrey LE (eds): Brain Metastases. Springer, New York, pp. 23-29, 2007.
  9. McKoy JM, Tigue CC, and Bennett CL. Does reimbursement affect physicians’ decision making? Examples from the use of recombinant erythropoietin. In Ethical Issues in Cancer Patient Care, Second Edition. Editor Peter Angelos. 2008, p. 235-51.
  10. Bennett, CL, Tigue CC, Fitzner KA. The Economics of Brain Metastases. In Brain Metastases (Cancer Treatment and Research). Raizer JJ and Abrey LE (eds.). New York, NY: Springer Publishing; 2007: 23-29.
  11. Norris, L. B., Magwood, J. and Bennett, C. L. Hematopoietic Growth Factors, in Cancer Consult: Expertise for Clinical Practice (eds S. A. Abutalib and M. Markman), John Wiley & Sons, Ltd, Oxford, UK. 2014. doi: 10.1002/9781118589199.

Abstracts

  1. Bennett CL, Ratain  MJ, Golomb HM.  Atypical mycobacteria infection and hairy cell leukemia. Blood. 64:161a, 1984.
  2. Bennett CL, Bitran J, Recant W, Putterman A, Shapiro CM, Karesh J, Kalohke V.  Staging and therapy in patients with orbital non-Hodgkin’s lymphoma.  Proceedings of the American Society of Ophthalmoplastic and Facial Surgery, oral presentation, 1985.
  3. Bennett CL, Vogelzang NJ, Potkul LJ, Reich SD.  Severe toxicity during a phase I trial of Vinblastine and Recombinant Interferon.  Proceedings of the International Society of Interferon Research, poster presentation, 1985.
  4. Bennett CL, Bitran J, Recant W, Putterman A, Shapiro C, Karesh J, Kalohke V.  Staging and therapy in patients with orbital non-Hodgkins lymphoma.  Proceedings of the American Society of Clinical Oncology, 4:C-767; 1985.
  5. Bennett CL, Ratain MJ, Larson RA, McMahon J, Daly KM.  Ventilation-perfusion scans may detect early invasive pulmonary aspergillosis.  Clinical Research, 33:852a; 1985.
  6. Lembersky BC, Ratain MJ, Bennett CL, Golomb HM, Vardiman J.  Osseous complications in hairy cell leukemia. Blood, 66(Suppl.):178a; 1985.
  7. Bennett CL, Vogelzang NJ, Chodak FW, Kellman HL. Zoladex versus orchiectomy in the management of stage D-2 prostate cancer. American Federation for Clinical Research, oral presentation, 34:950a, 1986.
  8. Bennett CL, Bitran JD, Goldsmith JM, Purl S, Golick J, Carlson T, Beckman E, Phair JD, Fisher   DL, Olson C, Harrington-Fowler L.  Quantitative T4 lymphocyte counts have prognostic significance in patients with ARC and AIDS. Poster presentation, Blood, 68(Suppl):362a; 1986.
  9. Daiter S, Magid D, Bennett CL, Bitran J, Purl S, Golomb HM. Communication and psychosocial adjustment among adult males with potentially fatal chronic disorders.  Blood, 68(Suppl):372a; 1986.
  10. Bennett CL, Vogelzang N, Ratain M, Potul L, Reich S.  Severe toxicity during phase I trial of Vinblastine and Recombinant gamma Interferon.  Proceedings of the American Society of Clinical Oncology, 5:C-872; 1986.
  11. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Weinstein J, Solarski A, Olaughlin K, Choi K. Pharmacokinetics and clinical toxicities of 72-hour continuous infusion of Etoposide (VP-16). Proceedings of the American Association of Cancer Research, C-714; 1986.
  12. Bennett CL, Garfinkle JB, Draper D, Rogers W, Matthews C, Kanouse D.  Hospital AIDS  experience and mortality in AIDS patients with Pneumocystis carinii pneumonia. Proceedings of the IVth International Conference on AIDS, poster presentation, Stockholm; 1988.
  13. Magid D, Daiter S, Bennett CL, Whaling S, Bitran J. Emotional distress among adult males with AIDS-related complex.  Poster presentation, Blood, 70:124a; 1987.
  14. Bennett CL, Bitran JD, Goldsmith JM, Phair JD, Fisher DL, Harrington-Fowler L, Jackson GG. Risk stratification of symptomatic patients with ARC based on T4 lymphocyte counts. Poster presentation, Blood, 70:a; 1987.
  15. Bennett CL, Ganz P, Aronow H, Elashoff RM, Greenfield S.  Patterns of care in the presentation and evaluation of patients with prostate cancer.  Proceedings of the American Society of Clinical Oncology, 7:128; 1988.
  16. Pascal AS, Bennett CL, Cvitanic M, Gorman M, Serrato C. Assessing the effects of state Medicaid and health insurance regulations on costs sharing for AIDS treatment expenses. Poster presentation, Proceedings of the VIth International Conference on AIDS, Stockholm; 1988.
  17. Bennett CL, Cvitanic MA, Pascal A. The costs of AIDS in Los Angeles. Poster presentation, Vth International Conference on AIDS; 1989.
  18. Bennett CL, Greenberg P, and Gulati S.  GM-CSF reduces hematologic toxicity and costs of care in patients with Hodgkin's disease undergoing autologous bone marrow transplantation. Oral presentation, Proceedings of the American Society of Hematology; 1990.
  19. Bennett CL, Gertler P, Guze PA The relation between hospital experience and mortality in VA Hospitals.  VIth International Conference on AIDS; 1990.
  20. Bennett CL, Adams J, Graf L, Hunter-Young N, DeHovitz JA, Daley J, Makadon H.  Intensity of in- hospital care for persons with AIDS.  Poster presentation, VIth International Conference on AIDS; 1990.
  21. Bennett CL, Adams J, Gertler P, Gilman S, Keesey J, Shapiro M, Brook RH, Park RE. 1987 volume-caseload relationship for HIV-related Pneumocystis carinii pneumonia (PCP) in New York City. Poster presentation, VIIth International Conference on AIDS; 1991.
  22. Bennett CL, Chang H, Shlian D, Dawson JA, Edlin B.  Clinical and economic aspects of HIV- disease in a Los Angeles student health service.  VIIth International Conference on AIDS; 1991.
  23. Cohn S, Bastian L, Kessler H, Edlin B, Waskin H, Forrest L, George L, DeHovitz J, Pitrak D, Dickinson G, Divine G, Shapiro M, Bennett CL.  Differences in severity of illness among patients with HIV-related Pneumocystis carinii pneumonia.  RAND/Duke/VA 4-city Quality of Care Study; 1991.
  24. Hynes D, Cohn S, Waskin H, Moran M, DeHovitz J, Archibald N, Dickinson G, Shapiro M, Bennett CL. RAND/Duke/VA multi-city quality of care study.  The Quality of Mercy for HIV-related Pneumocystis carinii pneumonia patients. VIII International Conference on AIDS; 1992.
  25. Bastian L, Bennett CL, Adams J, Waskin H, Divine G, Edlin B, Rodriguez D.  RAND/Duke/VA multi-city quality of care study.  Difference between men and women with HIV-related Pneumocystis carinii pneumonia: Experience from 3,70 Cases in New York City in 1987.  Poster presentation. VIII International Conference on AIDS; 1992.
  26. Bennett CL, Bastian L, Cohn S, Waskin H, Edlin B, Weinstein R, Archibald N, Gilman S, Dickinson G, Divine G, Shapiro M. RAND/Duke/VA. The volume-outcome relationship for HIV-related Pneumocystis carinii pneumonia multi-city quality of care study.  Poster presentation. VIII International Conference on AIDS, 1992.
  27. Bennett RL, Gilman S, George L, Guze PA, Bennett CL.  RAND/Duke/VA multi-city quality of care study.  Improved outcomes in intensive care units for AIDS-related Pneumocystis carinii pneumonia from 15 Veterans Administration Hospitals from 1987-1991.   IXth International Conference on AIDS; 1993.
  28. Bennett CL, Kessler H, Dickinson G, DeHovitz J, Weinstein RA, Shapiro MF. RAND/Duke/VA multi-city quality of care study.  The relationship between experience with AIDS and in-hospital mortality among Chicago, Los Angeles, and Miami Hospitals. Poster presentation. IXth International Conference on AIDS; 1993.
  29. Bennett CL, Armitage JL, Armitage GO, Schwartz SE, Bierman BJ, Vose JM., Armitage JO, Anderson JR.  A 'learning curve' exists in autologous transplantation for Hodgkin’s disease and non- Hodgkin's lymphoma as evidenced by improvements in cost and in-hospital mortality. Proceedings of the American Society of Hematology, 1993.
  30. Cassileth B, Bennett CL, Bastian L.  RAND/Duke/VA multi-city quality of care study. Racial differences in quality of care and outcome among patients with AIDS-related Pneumocystis carinii pneumonia (PCP).   Proceedings of the American Society of Clinical Oncology; 1994.
  31. Bennett CL, McLeod DG, Hillner BE. Estimating the cost-effectiveness of total androgen blockade (TAB) for stage D-2 prostate cancer.  Proceedings of the American Society of Clinical Oncology; 1994.
  32. Bastian L, Bennett CL, Sloane R.  Sex differences in quality of care among patients with AIDS- related Pneumocystis carinii pneumonia.  Association of Health Services Research and the Foundation for Health Services Research Conference; 1994.
  33. Chapman GB, Bennett CL, Elstein AS. Prostate cancer patients' utilities for health states: a pilot study.  Fourteenth Annual HSR&D Service Meeting, 1996.
  34. Chapman GB, Elstein AS, Andrews A, Alexander C, Bennett CL. Improving patient comprehension of time trade-off questions.  Sixth Biennial Conference on Medical Decision Making, 1996.
  35. Chapman GB, Bennett CL, Elstein AS. Prostate cancer patients' utilities for health states: a pilot study.  Proceedings of the American Society of Clinical Oncology, 1996.
  36. Bennett CL, Curtis JR, Shaw-Taylor Y, Horner RD, Achenbach C, Bennett R, Andrulis D.  U.S. hospital care for HIV-infected persons and the role of public, private, and Veterans Administration Hospitals. Proceedings of the XI International Conference on AIDS, Th.D.5027, Vancouver, B.C., 1996.
  37. Pajeau TS, Bennett CL, Horner RD, Curtis JR, Weinstein RA, DeHovitz JA.  Differences in care patterns for intravenous drug users with AIDS-related PCP. Poster presentation. Proceedings of the XI International Conference on AIDS, We.C.3406, Vancouver, B.C., July 1996.
  38. Curtis JR, Horner RD, Bennett CL.  Survival from intensive care for patients with HIV-related PCP. XI International Conference on AIDS, Tu.B.111, Poster presentation. Vancouver, B.C., July 1996.
  39. Gulati SC, Bennett CL.  Cost-effectiveness analysis in growth factor use.  25th International Meeting of the International Society for Experimental Hematology, Oral presentation, Hamburg, Germany, June 1997.
  40. Bennett CL, Golub R, Waters T, Tallman M, Rowe J.  Economic analysis of GM-CSF as adjunct therapy for adults with AML.  Poster presentation. Proceedings of the American Society of Hematology, 88(10, Suppl 1.): 209a; 1996.
  41. Pajeau ME, Waters AT, Bennett CL.  Cost identification analysis of prostate cancer screening in a rural hospital network.  Proceedings of the American Urological Association, Poster Presentation, 1997.
  42. Kozloff MS, Horner RD, Bennett CL, Mullen J, Kuzel TM. Racial variations in prostate cancer stage diagnosis in an equal access medical system. Proceedings of the American Urological Association, 1997 Annual Meeting, Poster Presentation, April 1997.
  43. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Bennett CL.  Alternative strategies for assessing patient preferences for prostate cancer. American Urological Association, 1997 Annual Meeting, Oral Presentation, April 1997.
  44. Pajeau TS, Waters TM, Bennett CL, Pavletic ZS, Tarantolo SR, Bishop MR. Economic analysis of allogeneic blood stem cell vs. allogeneic bone marrow transplantation for hematologic malignancies. Poster presentation. Proceedings of the American Society of Clinical Oncology, 16:419a; 1997.
  45. Seday MA, Kaplan J, Bennett CL, Kuzel TM, Sartor O.  Low literacy, but not race, predicts presence of metastatic prostate cancer at initial presentation in the VA medical system. Oral presentation, Proceedings of the American Society of Clinical Oncology, 1997.
  46. Bennett CL, Buchner D, Ullman M.  Managed care organizations await the outcomes of the ASCO prostate cancer guidelines. Proceedings of the American Society of Clinical Oncology, 1997.
  47. Bennett CL, Weinstein J, Medio FJ, Golub R.  Treatment considerations for physicians prescribing cis-platinum chemotherapy: an international perspective. Poster presentation. Proceedings of the American Society of Clinical Oncology, 1997.
  48. Pajeau TS, Lane D, Bennett CL, Land V, Amylon M, Laver JH.  Economic analysis of G-CSF use with intensive treatment for pediatric lymphoma and T-cell leukemia. Poster presentation, Proceedings of the American Society of Hematology, 1997.
  49. Weinberg PD, Bennett CL, Rozenberg-Ben-Dror K, Yarnold PL, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: age and treatment associated mortality. Poster presentation. Blood, 90(10): 462a; 1997.
  50. Bennett CL, Golub RM, Calhoun EA, Weinstein J, Fishman D, Lurain J, Roland P, Medio F, Bukowski RM.  Cost utility of amifostine in first line therapy for ovarian cancer. Eighth International Congress on Anti-Cancer Treatment, Paris-France, February 3rd - 6th, 1998.
  51. Bennett CL, Lane D, Pajeau TS, Büntzel J.  Amifostine as adjunct therapy in head and neck cancer: implications for economic analyses of phase II clinical trials.  Eighth International Congress on Anti- Cancer Treatment, Paris-France, February 3rd - 6th, 1998.
  52. Bennett CL, Golub RM, Pajeau TS, Aboulafia DM, Von Roenn J, Stewart S.  A cost-effectiveness analysis of liposomal anthracyclines for HIV-related Kaposi’s sarcoma. Eighth International Congress on Anti-Cancer Treatment, Paris-France, February 3rd - 6th, 1998.
  53. Yang T, Pajeau TS, Bennett CL.  Cost and effectiveness in salvage chemotherapy for epithelial ovarian carcinoma.  Twenty-Third Annual Congress of the Oncology Nursing Society, May 7-10, 1998.
  54. Weinberg PD, Bennett CL, Tosteson T, Ross S. Is flutamide effective for total androgen blockade: results of an updated literature-based meta-analysis. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology.  17:427a; 1998.
  55. Bennett CL, Somerfield M, Feinglass J, Smith TJ.  Decrease in misuse/overuse of HCSFs for solid tumors and lymphomas: results from ASCO surveys related to the 1994 and 1996 ASCO CSF guidelines. Oral presentation.  Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology.  17:421a; 1998.
  56. Bishop MR, Bennett CL, Tallman M, Somerfield MR, Feinglass J, Smith TJ.  Hematopoietic colony stimulating factors as adjunct therapy for elderly patients with acute myelogenous leukemia: results from the 1997 ASCO CSF survey related to the 1994 and 1996 ASCO CSF guidelines. Poster presentation, Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology. 17:20a; 1998.
  57. Calhoun E, Bennett CL, Lurain J, Weinstein J, Fishman D. Comparison of ovarian cancer patients’ and gynecologic oncologists’ utility scores regarding chemotherapy-induced toxicities. Proceedings of the American Society of Clinical Oncology. 17:49a; 1998.
  58. Knight S, Yarnold P, Kuzel T, Sharp L, Falcone D, Bennett CL.  Satisfaction with care and quality of life in metastatic prostate cancer: when less is more. Poster presentation. Proceedings of the American Society of Clinical Oncology.  17:414a; 1998.
  59. Pajeau TS, Golub RM, Waters TM, Tallman M, Rowe J, Bennett CL.  The benefit of multisite data  to cost analyses: an example of GM-CSF as supportive therapy for elderly patients with AML. Poster Presentation.  Proceedings of the American Society of Clinical Oncology.  17:417a; 1998.
  60. Lane DR, Pajeau TS, Büntzel J, Bennett CL.  Analyzing clinical and economic benefits of novel therapeutic agents in phase II clinical trials.  Proceedings of the American Society of Clinical Oncology.  17:417a; 1998.
  61. Fishman DA, Calhoun E, Golub R, Weinstein J, Lurain J, Roland P, Medio F, Bennett CL. Cost- utility assessment of amifostine in first-line therapy for ovarian cancer. Proceedings of the American Society of Clinical Oncology. 17:417a; 1998.
  62. Schwartz D, Lane DR, Calhoun EA, Bhattacharya M, Weinstein R, Phair J, Yarnold PR, Bennett CL.  The relation between in-hospital TB and PCP experience and quality of HIV-related tuberculosis care.  12th World AIDS Conference, June 1998.
  63. Bhattacharya M, Lane DR, Calhoun EA, Schwartz D, Weinstein R, Phair J, Yarnold PR, Bennett CL.  Race, age, gender and risk-group differences in rates of suspicion for HIV-related tuberculosis. 12th World AIDS Conference, June 1998.
  64. Yang T, Pajeau TS, Bennett CL.  Cost and effectiveness in salvage chemotherapy for epithelial ovarian carcinoma.  Twenty-Third Annual Congress of the Oncology Nursing Society, May 7-10, 1998.
  65. Pajeau TS, Golub RM, Waters TM, Tallman MS, Rowe JW, Bennett CL. The benefit of multisite data to cost analyses: An example of GM-CSF as supportive therapy for elderly patients with AML. Proceedings of the American Society of Clinical Oncology 17:1606; 1998.
  66. Lane DR, Pajeau TS, Büntzel J, Bennett CL.  Analyzing clinical and economic benefits of novel therapeutic agents in phase II clinical trials. Proceedings of the American Society of Clinical Oncology 17:1607; 1998.
  67. Bennett CL, Waters TM, Stinson TJ, Almagor O, Sobocinski KA, Klein JP, Rowlings PA, Horowitz M.  Analysis of short-term costs of allogeneic transplantation: results from the international blood and marrow transplant registry/Northwestern University economic data base project.  Blood 92 (10): 551a, 1998.
  68. Waters TM, Bennett CL, Stinson TJ, Winter J, Almagor O, Sobocinski KA, Klein JP, Rowlings PA, Horowitz M. The cost of autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma and breast cancer: results from the autologous blood and marrow transplant registry/Northwestern University economic data base project.  Blood 92(10): 1906a, 1998.
  69. Bennett CL, Hynes D, Godwin J, Stinson TJ, Golub RM, Appelbaum FR. Economic analysis of granulocyte colony-stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia:  Estimates from a Southwest Oncology Group Clinical Trial.  Blood 92(10): 2538a, 1998.
  70. Friedberg M, Saffron B, Nelson W, Stinson TJ, Bennett CL.  Conflict of interest in pharmaceutical- sponsored cost-effectiveness studies in hematology/oncology. Proceedings of the American Society of Clinical Oncology 18:414a; 1999.
  71. Stinson TJ, Frey P, Knight S, Traynor A, O'Gara K, Bennett CL, Winter JN. Outpatient autologous stem cell transplant is associated with cost-savings and a similar quality of life. Blood 94(10): 400a, 1999.
  72. Frey P, Stinson TJ, Knight S, Traynor A, Bennett CL, Winter JN.  Lost opportunity costs contribute to family burden associated with outpatient autologous stem cell transplantation.  Blood 94(10): 184a; 1999.
  73. Knight SJ, Chapman GB, Elstein AS, Chmiel JS, Kim SP, Bennett CL. Perceived involvement in care, patient satisfaction, and patient-clinician agreement about prostate cancer utilities. Proceedings of the American Society of Clinical Oncology 18:411a; 1999.
  74. Chapman GB, Elstein AS, Chmiel JS, Kim SP, Bennett CL. What’s really important? Disagreement and agreement between prostate cancer patients and their clinicians about attribute importance. Proceedings of the American Society of Clinical Oncology 18:411a; 1999.
  75. Kim SP, Knight SJ, Kuzel T, Moran EM, Falcone D, Bennett CL. The European Organization and Research for Treatment of Cancer: A reliable measure of disease progression in prostate cancer. Proceedings of the American Society of Clinical Oncology 18:411a; 1999.
  76. Calhoun EA, Fishman DA, Roland PY, Lurain JR, Bennett CL. Total cost of chemotherapy-induced hematologic and neurologic toxicity. Proceedings of the American Society of Clinical Oncology 18:414a; 1999.
  77. Thrasher J, Deeths J, Bennett CL, Iyer P, Steidle C, McLeod DG. Comparative study of the clinical efficacy of 500 mg qD vs. 250 mg tid dosing of flutamide in metastatic prostate cancer.  Proceedings of the American Society of Clinical Oncology, volume 19, *1315, 2000.
  78. Buentzel J, Glatzel M, Kuettner K, Froehlich D, Bennett CL, Calhoun E. Late toxicities due to multimodal treatment of head and neck cancer (HNC). Proceedings of the American Society of Clinical Oncology, volume 19, *1629, 2000.
  79. Stinson TJ, Bennett CL, Vogel V, Leedy D, Hobbs J, Ruckdeschel JC, Chirikos TN, Weiner RS, Wicha MS.  A multi-center study of the costs of enrolling cancer patients on phase II clinical trials. Proceedings of the American Society of Clinical Oncology, volume 19, *1695, 2000.
  80. Knox KS, Adams JR, Stinson TJ, Bennett CL. Comparison of methodologic quality of non-profit vs. pharmaceutical analyses of six breakthrough oncology drugs. Proceedings of the American Society of Clinical Oncology, volume 19, *1700, 2000.
  81. Bennett CL, Stinson TJ, Bhoopalam N, Marriott M, Panganiban J, Kozloff MF. A double blind, randomized trial of toxicity, resource use and costs for filgrastim and sargramostim.  Proceedings of the American Society of Clinical Oncology, volume 19, *1712, 2000.
  82. Domagk KR, Werner E, Büntzel J, Bennett CL. Pharmacoeconomic study in patients with head and neck cancer (HNC). Proceedings of the American Society of Clinical Oncology, volume 19, *1728, 2000.
  83. Slimack N, Knight SJ, Siston AK, Kim SJ, Chmiel J, Chan C, Bennett CL. Emotional and role functioning decrements are shot-lived for metastatic prostate cancer patients following castration. Proceedings of the American Society of Clinical Oncology, volume 19, *1731, 2000.
  84. Hounshell J, Knox K, Rundhaugen L, McCarville M, Tomori C, Bennett CL, Tallman M. Adverse effects of hairy-cell leukemia on patient insurance status. Proceedings of the American Society of Clinical Oncology, volume 19, *1734, 2000.
  85. Knight SJ, Siston AK, Slimack N, Cheeling C, Chmiel JS, Kim S, Bennett CL. Racial differences in quality of life among veterans with localized prostate cancer. Proceedings of the American Society of Clinical Oncology, volume 19, *1735, 2000.
  86. Siston AK, Kim SP, Slimack NP, Knight SJ, Chmiel JS, Chan C, Bennett CL. Cancer specific quality of life (QOL) assessments differ among localized prostate cancer (PCA) patients (Pts) treated with hormone/radiation therapy (H/XRT), radical prostatectomy (RP), or watchful waiting (WW). Proceedings of the American Society of Clinical Oncology, volume 19, *1750, 2000.
  87. Adams JR, Stinson TJ, Bennett CL, Bishop MR. Economic analysis of phase III study of G-CSF post alloPBSCT: clinically effective and decreases follow-up costs. Proceedings of the American Society of Clinical Oncology, volume 19, *1771, 2000.
  88. Lloyd KG, Engebretson AJ, Adamczyk P, Tomori C, Lyons T, Bennett CL. Out-of-pocket costs and lost wages associated with colorectal, breast, and prostate cancer care. Proceedings of the American Society of Clinical Oncology 20:241a; 2001.
  89. Calhoun EA, Welshman EE, Chang C-H, Lurain JR, Bennett CL. Cost of chemotherapy-induced neutropenia, thrombocytopenia, and neurotoxicity. Proceedings of the American Society of Clinical Oncology 20:242a; 2001.
  90. Bennett CL, Adams J. Cost-identification of Doxil versus topotecan for relapsed ovarian cancer in the United States. Proceedings of the American Society of Clinical Oncology 20:249a; 2001.
  91. Adams JR, Elting LS, Lyons T, Demetri GD, Lembersky BC, Bennett CL. Evaluation of EPO use and direct-to-consumer marketing effects: Results from a survey of American and international hematologists and oncologists. Proceedings of the American Society of Clinical Oncology 20:249a; 2001.
  92. Phan LT, Lee JU, Calhoun EA, Bennett CL. An updated look at the societal cost of toxicity management and out-of-pocket costs for patients and their caregivers. Proceedings of the American Society of Clinical Oncology, 21:254a, 2002.
  93. Bennett CL, Nathan DP, Adams JR.  Epoetin alfa use for cancer patients in the United States and Europe: review of vignette and clinical data. Proceedings of the American Society of Clinical Oncology, 2002.
  94. Newlin RC, Gibbons KC, Phan L, Ferreira MR, Dolan NC, Fitzgibbon ML, Davis TC, Bennett CL. Relation between education, age, race and rate of colorectal cancer screening recommendation. Proceedings of the American Society of Clinical Oncology, 2002
  95. Nathan DP, Siston AK, Wolf MS, Golub R, Bennett CL, Knight SJ. Treatment decision intervention for prostate cancer patients.  Proceedings of the American Society of Clinical Oncology, 2002.
  96. Bennett CL, Lyons E, Auerbach A, Ladewski L, Raisch D. System barriers limit timely and comprehensive reporting of adverse drug reactions (ADRs): experience from five recently reported hematologic ADRs. Proceedings of the American Society of Hematology, 2002.
  97. Ladewski L, Auerbach A, Lyons E, Raisch D, Evens A, Bennett CL. Drug-associated TTP/HUS: a review of clinical finding, FDA reports, and package insert information for the four drugs most commonly reported with the syndrome. Proceedings of the American Society of Hematology, 2002.
  98. Bennett CL, Ladewski LA, Auerbach AR, Lyons EA, Kim B. Accelerated FDA approval of cancer drugs is associated with post-marketing identification of common, but potentially fatal adverse drug reactions (ADRs).  Proceedings of the American Society of Clinical Oncology, 2003.
  99. Auerbach AR, Lee JU, Bennett CL. Association between out-of-pocket costs and patient insurance type for caregivers of breast cancer patients.  Proceedings of the American Society of Clinical Oncology, 2003.
  100. Ladewski LA, Wolf MS, Bennett CL.  Barriers to recruitment of African Americans to the Selenium and Vitamin E Cancer Prevention Trial (SELECT): Focus group findings. Proceedings of the American Society of Clinical Oncology, 2003
  101. Heckinger E, Lee JU, Calhoun E, Bennett CL. Cost minimization analysis of filgrastim (C-CSF) versus pegfilgrastim (peg-G-CSF) for stage II-IV breast cancer patients receiving chemotherapy: Assessments based on third-party and societal perspectives.  Proceedings of the American Society of Clinical Oncology, 2003.
  102. Lee JU, Auerbach A, Bennett CL. Estimates of out-of-pocket expenditures incurred by breast cancer patients. Proceedings of the American Society of Clinical Oncology, 2003.
  103. Knight SJ, Lyons EA, Ray P, Wolf MS, Cleofe J, Colella KM, Golub RM, Arseven A, Bennett CL. Are equal access systems equally accessed? Pretreatment comparison of men with prostate cancer   seen at a VA and a county hospital.  Proceedings of the American Society of Clinical Oncology, 2003.
  104. Lyons EA, Wolf MS, Lai JS, Taft R, Colella KM, Cella D, Bennett CL. Computer-based testing  may be less practical in clinical settings with patients with lower education levels.  Proceedings of the American Society of Clinical Oncology, 2003.
  105. Weininger R, Mullaly K, Quigley J, Wieting G, Lee JU, Heckinger E, Calhoun E, Bennett CL. Indirect and direct costs associated with a febrile neutropenic event.  Proceedings of the American Society of Clinical Oncology, 2003.
  106. Chacko RJ, Lyons EA, Tallman MS, Belknap SM, Raisch D, Fotis M, Trifilio S, Kuzel TM, Slimack N, Bennett CL.  Gemtuzumab Ozagomicin (GO(Mylotarg)) Associated Sinusoidal Obstructive Syndrome (SOS) Occurs at Higher Rates in Off-Label Clinical Settings: An Overview of Cases Reported to the FDA and in the Medical Literature.  BLOOD, 102 (11), part 1: 749a.
  107. Heckinger EA, Bennett CL, Davis T, Wolf MS. Health Literacy and cancer care: So patients really understand? Proceedings of the American Society of Clinical Oncology Annual Meeting, 2004.
  108. Wolf MS, Heckinger EA, Arozullah A, Costello SR, Yarnold PR, Slotysik PC, Bennett CL. Identifying persons with poor health literacy in 7 seconds: An important adjunct to improving cancer screening and treatment. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2004.
  109. Dolan NC, Ferreira MR, Gorby NS, Fitzgibbon MS, Rademaker A, Liu D, Davis TC, Schmitt BP, Wolf MS, Bennett CL. Increasing colorectal cancer screening using a targeted, low literacy intervention. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2004.
  110. Gorby NS, Wolf MS, Bennett CL. Introducing HIPAA: Triple the cost and triple the time for patient recruitment to the SELECT study. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2004.
  111. Rolub RM, Knight SJ, Pickard S, Kramer K, Lyons EA, Arseven A, Wolf MS, Colella KM, Bennett CL. Problems measuring prostate-related utilities in low-literacy patients. Proceeedings of the American Society of Clinical Oncology Annual Meeting, 2004
  112. Lyons EA, Knight SJ, Wolf MS, Arseven A, Golub RM, Kramer K, Colella KM, Ray P, Cleofe J, Bennett CL. Race and literacy effects of prostate cancer biology and access. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2004.
  113. Arseven A, Wolf MS, Lyons EA, Pickard S, Golub RM, Knight SJ, Kramer K, Colella K, Bennett CL. Shared decision making for older, poor, newly diagnosed prostate cancer patients may not be possible. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2004.
  114. Finley DK, Arozollah A, Heckinger EA, Calhoun EA, Wolf M, Fitzner KA, Gorby NS, Schumock GT, Bennett CL. Less money, more problems: The financial burden of breast cancer on lower income women. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2004.
  115. Franks ME, Price DK, MacPherson G, Singh A, Linehan WM, Bennett CL, Figg WD. Evaluation of the endostatin polymorphism D104N in prostate cancer. Proceedings of the American Urological Association Annual Meeting, 2004.
  116. Lyons EA, Wolf MS, Knight SJ, Bennett CL. Evaluating genitourinary symptoms prior to therapy is essential when reporting on treatment related toxicities for newly diagnosed prostate cancer patients. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2005.
  117. Brwon SO, Calhoun E, Bennett CL. Overall quality of life (QoL) is not meaningfully affected by severity of pegylated liposomal doxorubicin (PLD)-associated palmar-plantar erythrodyesthesia (PPE) among women with metastatic breast cancer. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2005.
  118. Costello S, Wolf MS, Lyons EA, Ray P, Kozloff M, Bennett CL. Variations in treatment of lower SES prostate cancer patients at a VA, a county and a private hospital. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2005.
  119. Powell EF, Ferreira MR, Dolan NC, Fitzgibbon ML, Davis TC, Liu D, Rademaker AW, Wolf MS, Bennett CL. Benefits of a free lunch: Final results of a randomized controlled trial evaluating a free lunch-continuous quality improvement intervention for colorectal cancer (CRC) screening in the Veterans Administration (VA) health care system. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2005.
  120. Evens AM, McKoy JM, Angelotta C, Yarnold PR, McCaffrey KR, and Bennett CL. Thalidomide- Associated Thromboembolism in Cancer; Reimbursement for Thalidomide’s “Off-Lable” Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns. American Society of Hematology; poster presentation. December 11, 2005.
  121. Bennett CL, Frohlich LE, Angelotta C, McCaffrey KR, McKoy JM, Ramsey GE, and Lindenberg JS. National Responses to HIV Versus HCV-Infection from Virally Contaminated Blood Products among Persons with Hemophilia (PWH): More Different Than Alike. American Society of Hematology: poster presentation. December 12, 2005.
  122. Pomeranz H, Angelotta C, Raisch DW, Bennett CL. Sildenafil-and Tadalafil-Associated Optic Neuropathy: An Overview from the Research on Adverse Events and Reports (RADAR) Project. Association for Research in Vision and Ophthalmology (ARVO): poster presentation. April 2006.
  123. Angelotta C, Lurie AJ, Yarnold PR, Singhal S, Mehta J, Lyons EA, and Bennett CL. Black Box Warning on lenalidomide-associated venous thromboembolism (VTE) in off-label setting: A preemptive and unusual safety initiative. American Society of Clinical Oncology. Accepted for poster presentation. June 2006.
  124. Bennett CL, Angelotta C, Lurie AK, Lyons EA, Yarnold PR and Raisch DW. Complementary systems: Quality and timeliness of passive vs. active adverse event reporting and regulatory vs. peer- reviewed adverse drug reaction (ADR) dissemination. American Society of Clinical Oncology. Accepted for poster presentation. June 2006
  125. Lurie AJ, Djulbegovic B, Nebeker JR, Angelotta C, Gordon LI, Raisch DW, Yarnold PR, Carson KR, McKoy JM, and Bennett CL. Do post-approval phase III trials for accelerated approved cancer drugs violate equipoise? American Society of Clinical Oncology. Accepted for poster discussion. June  2006.
  126. Zagory JA, Chang C, Carson K, Bennett CL. Race and health literacy associated variations in quality of life (QOL) following treatment for veterans with newly diagnosed localized prostate cancer (PCa). Proceedings of the American Society of Clinical Oncology Prostate Symposium, 2006.
  127. Chang C, Hyland S, Zagory JA, Bennett CL. Prostate cancer in Hispanics: An emerging focus in patient concern? Proceedings of the American Society of Clinical Oncology Prostate Symposium, 2006.
  128. Bennett CL, Sartor O, Susan H, Kattan MW, Scardino PT. Prostate cancer (PCa) care varies by race, region, and literacy: Initial findings from COMPARE. Proceedings of the American Society of Clinical Oncology Prosate Symposium, 2006.
  129. Chang C, Knight SJ, Bennett CL. Effects of depression on quality of life in Medicare beneficiaries with prostate cancer. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2006.
  130. Sartor O, Bennett CL, Halabi S, Kattan M, Scardino P. Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2006.
  131. Zagory JA, Chang CH, Knight S, Lyons EA, Bennett CL. Urinary dysfunction appears to be the primary determinant of castration versus observation for prostate cancer patients with PSA failure. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2006.
  132. Wolf MS, Zagory JA, Chang C, Knight S, Ray P, Kozloff M, Starr A, Lyons EA, Costello S, Bennett CL. Literacy and race predictors in localized prostate cancer treatment choice. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2006.
  133. Witt WP, Pickard S, Kuzel T, McDade T, Perry S, Hung S, Zagory J, Lin H, Costello S, Colella K, Bennett CL. Relationship between biological and self-reported measures of stress among informal caregivers of patients with prostate cancer. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2006.
  134. Bennett CL, Sartor O, Halabi S, Kattan M, Scardino P. Variations in prostate cancer care according to race, geographical region, and literacy: Initial findings from the COMPARE registry. Proceedings of the American Urological Association Annual Meeting, 2006.
  135. Zagory JA, Chang C-H, Carson K, Bennett CL. Race/ethnicity and health literacy associated variations in quality of life (QOL) following treatment for Veterans with newly diagnosed localized prostate cancer (PCa). Proceedings of the American Urological Association Annual Meeting, 2006.
  136. Wolf MS, Knight SJ, Durazo-Arvizu R, Pickard AS, Lyonds EA, Arsevan A, Arozulla A, Colella K, Witt W, Bennett CL. Relation between literacy, race and PSA level among men with newly diagnosed prostate cancer. Proceedings of the American Urological Association Annual Meeting, 2006.
  137. Nonzee NJ, Brown SO, Chang CH, Evens AM, Gordon LI, Winter JN, Bowman L, Kutikova L, Bennett CL. Out-of-pocket costs and quality of life (QOL) for patients with Hodgkin’s Disease (HD), Indolent Non-Hodgkin’s Lymphoma (INHL), and Aggressive Non-Hodgkin’s Lymphoma (ANHL).
  138. Bennett CL, Kline K, Sartor O. Health-related quality of life (HRQOL) among long-term survivors of prostate cancer treated with external beam radiation therapy (EBRT) with or without hormonal therapy: Findings from the COMPARE Registry. Proceedings of the American Society for Clinical Oncology Prostate Symposium, 2007.
  139. Bennett CL, Dandade N, Sartor O.  Veterans’ Administration Patterns of Care: More Aggressive at Initial Diagnosis, Less Aggressive Later. Proceedings of the American Society for Clinical Oncology Prostate Symposium, 2007.
  140. Bennett CL, Angelotta C, Nebeker JR, Dorr DA, Tigue CC, Raisch DW. Augmenting FDA and Pharmaceutical Manufacturer Passive Pharmacovigilance Efforts: Potential Benefit of Collaboration with VA Pharmacovigilance Program. Veterans Administration Health Services Research and Development Service National Meeting. February 2007. Abstract 1010.
  141. Gleason K, Tigue C, Yarnold P, McKoy J, Angelotta C, Courtney DM, Edwards B, Bohlius J, Bennett CL. Recombinant Erythropoietin (EPO)/Darbepoetin (Darb) Associated Venous Thromboembolism (VTE) in the Oncology Setting: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project. American Society of Clinical Oncology: poster presentation. June 5, 2007.
  142. Angelotta C, Dorr D, West D, Burdon R, Lagman J, Workman D, Hurdle J, Belknap SM and Bennett CL. New IRB guidelines: Will cancer patient safety improve? American Society of Clinical  Oncology: poster discussion. June 5, 2007.
  143. Zakarija A, Bandarenko N, Kwaan H, Pandey D, Cursio J, Tevar A, Buffie C, Weiss I, Ortel T, Winters J, Kiss J, Sarode R, Bennett CL. Risk factors for thrombotic thrombocytopenic purpura: results of the Surveillance, Epidemiology, and Risk Factors for TTP (SERF-TTP) group. J. Clin Apheresis. 2007; 22:51-52. Abstracts of the 28th Annual Meeting of the American Society for Apheresis.
  144. Zakarija A, Kwaan HC, Banderanko N, Pandey DK, Cursio JF, Weiss IM, Luu TH, Winters JL, Ortel TL, Raife TJ, Sarode R, Bennett CL.  Distinct Clinical Syndromes are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study. Blood. Nov 2007; 110 (11): # 1320.
  145. Bennett CL, Luu TH, Zakarija A, Bandarenko N, Pandey DK, Kwaan HC, Cursio JF, McKoy JM, Buffie C, Winters JL, Ortel TL, Sarode R, Zhen XL, Raife TJ, Matsumoto M, Fujimura Y, Rock G. Clinical and outcomes findings for thrombotic thrombocytopenic purpura among 467 persons with severely versus non-severely deficient ADAMTS13 levels. Blood. Nov 2007; 110 (11): #2088.
  146. Richey E, Bennett CL, Kwaan HC, Zakarija A, Banderanko N, Pandey DK, McKoy JM, Yarnold   PR, Raisch DW, Winters JL, Raife TJ, Cursio JF, Fisher MJ, Ortel T, Tallman MS, Matsumoto M, Fujimura Y, Moake J. Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group. Blood. Nov 2007; 110 (11): #2089.
  147. Pandey DK, Zakarija A, Bandarenko N, Cursio J, Luu TH, Winters J, Sarode R, Kiss J, Bennett CL. Antiplatelet/Anticoagulant therapy and Risk of Thrombotic Thrombocytopenic Purpura (TTP): Surveillance, Epidemiology and Risk Factors for TTP (SERF-TTP) Study, 2002-2007. Accepted as an oral presentation at ASFA 2008.
  148. S. B. Hammerman, D.P. West, C.L. Bennett, M.E. Lacouture. Variability in the reporting of dermatologic adverse reactions dADRs) to EGFR inhibitors cetuximab (C) and panitumumab (P) in the treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 15045)
  149. E. McCarthy, N.A. Dandade, C.L. Bennett. Veterans with prostate cancer talking about life experiences (VA T.A.L.E.S.) A pilot study. J Clin Oncol 26: 2008 (ay 20 suppl; abstr 16124)
  150. T. Abraham, A. Rademaker, S. Ortiz, C.L. Bennett, E. Richey, N.J. Nonzee, D.P. West, J.D. Patel, M.E. Lacouture. Economic impact associated with the management of dermatologic adverse drug reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 19094.
  151. N.U. Yedavalli, J. Lagman, N.A. Dandade, A.M. Evens, H. Munshi, B. Jovanovic, L. Gallot, C.L. Bennett. Effect of zoledronate (Z) on bone mieral density (BMD) among African Americans (AA) with advanced prostate cancer, without skeletal metastases, receiving androgen ablation therapy. J Clin Oncol 26: 2008 (May 20 suppl; abst 16031.
  152. D. M. Hynes, E. Tarlov, T. Lee, R. Perrin, Q. Zhang, M. Ferreira, R.A. Durazo-Arvizu, A. B. Benson, D. J. Bentrem, C. L. Bennett. Examining disparities in colon cancer treatment patterns. J Clin Oncol
    26: 2008 (May 20 suppl; abstr 6534)
  153. C. L. Bennett, J. L. Lagman, J.M. McKoy, D. M. Courtney, S.M. Belknap, A. O. Sartor, B. Djulbegovic, D. P. West. Research on Adverse Drug Events and Reports (RADAR) Project. RADAR assessment of quality of reporting of serious adverse drug reactions (sADRs) to an Institutional Review Board (IRB) for 14 clinical trials with imatinib mesylate. J Clin Oncol 26: 2008 (May 20 suppl; abstr 8531)
  154. K.R. Carson, A. M. Evens, L.I. Gordon, J.F. Seymour, S.T. Rosen, N. Gottardi-Littell, K. Muro, E. Richey, C.L. Bennett. Rituximab and progressive multifocal leukoencephalopathy: A report of 35 cases. J Clin Oncol 26: 2008 (May 20 suppl; abstr 8531)
  155. M.A.Simon, N.J. Nonzee, J.M. McKoy, A. Rademaker, P.J. Byer, J. Feinglass, E.A. Calhoun, J. Darnell, R. Massenburg, C.L. Bennett. The role of health literacy in patient navigation intensity prior to and post-prostate cancer diagnosis. J Clin Oncol 26: 2008 (May 20 suppl; abstr 17534)
  156. A. Kuykendal, C.L. Bennett, J.M. McKoy, S. Boyle, D. P. West, B.J. Edwards, D.M. Courtney, A.O. Sartor, S. Y. Lai, M. Henke. Tumor progression and mortality associated with administration of erythropoiesis stimulating agents (ESAs) to cancer patients: Is toxicity due to ESAs or elevated hemoglobin (Hgb) levels? J Clin Oncol 26: 2008 (May 20 suppl; abstr 11115)
  157. J.M. McKoy, A.O. Sartor, M. Henke, D.P. West, D.M. Courtney, K.R. Carson, B.J. Edwards, A.T. Samaras, C.L. Bennett. Erythropoiesis stimulating agents (ESAs): An overview of safety-related findings from the Research on Adverse Drug Events and Reports (RADAR) project. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6635)
  158. M. Henke, C.L. Bennett, J.M. McKoy, B.J. Edwards, D.M. Courtney, D.P. West, A.T. Samaras,A.O. Sartor, D.M. Spiegel. The importance of timely and appropriately-sized pharmacovigilance studies in the detection of safety signals: Lessons learned from the erythropoiesis stimulating agents (ESAs) controversy. J Clin Oncol 26:2008 (May 20 suppl; abstr 6532)
  159. Stafkey-Mailey D, Bennett CL, Dickson M. Racial/Ethnic Disparities of Erythropoiesis Stimulating Agent Use Among the Insured Poor:  Pre- and Post-Safety Advisories. American Society of Hematology; podium presentation. December 6, 2010.
  160. Bennett CL, Qureshi ZP. Finishing the picture: Clopidogrel is indeed the most common drug associated with thrombotic thrombocytopenic purpura (TTP) in FDA databases: Its mechanism, laboratory findings, clinical features, and epidemiology differ from that associated with ticlopidine. American Society of Hematology; poster presentation. December 4, 2010.
  161. Qureshi Z,  Cunningham JE, Heiney SP, Bennett C. Axillary Lymph Node Dissection versus Sentinel Lymph Node Biopsy: Breast Cancer Survivors from The ABC Study. Poster presentation at Chalsty Breast Cancer Research Conference, Medical University of South Carolina Hollings Cancer Center, February 24, 2012.
  162. Rao G, Georgantopoulos P, Hadoock KS, Carson K, Norris L, Sartor O, Bennett C. First estimates of incidence of Progressive Multifocal Leukoencephalopathy developing among 10,459 non-HIV lymphoma VA patients who receive Rituximab: Results from the Veterans Administration Database (1999-2012). American Society of Hematology; poster presentation. December 2012.
  163. Bennett CL, Zhu  NY,  Murday AS, Dy IA, Baumbach J, Magwood JS, Georgantopoulos P,  Singh S. Cocaine- levamisole associated neutropenia and thrombovasculopathy: A novel syndrome. American Society of Hematology; poster presentation. December 2012.
  164. Lu Z, Qureshi Z, Felder T, Lopez I, Chen B, Xirasagar S, Sartor O, Bennett C. Why is Cancer Care So Expensive: Potential Implications of Fraud and Abuse. American Society of Hematology; poster presentation. December 2012.
  165. Bennett CL, Matsumoto M, Fujimura Y, Georgantopoulos P, Dunn BL. Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations from Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000. American Society of Hematology; poster presentation. December 2012.
  166. Trenery A, Kessler S, Lebby A, Van Slooten E, Bialkowski M, Byrne A, Boyle S, Ray P, Raisch DW, Norris L, Rao G, Georgantopoulos P, Yarnold P, Sartor O, Bennett CL. Conflicts of Interest in Pharmaceutical Sponsored Research on Erythropoietin Receptors in Cancer: An Updated Analysis. American Society of Hematology; poster presentation. December 2013.
  167. Norris L, Georgantopoulos P, Rao G, Bennett CL. Association between Rituximab Use and Progressive Multifocal Leukoencephalopathy among non-HIV Non-Hodgkin’s Lymphoma Veteran’s Administration Patients. American Society of Hematology Meeting on Lymphoma Biology; poster presentation. August 2014.

Invited Presentations (Selected)

  1. American Society of Clinical Oncology Annual Meeting, “Introducing Navigator Harlem to the Nation.” Atlanta, GA, June 2006.
  2. Erythropoeitin: Is it overused? May 2006. ASCO Atlanta, GA
  3. “RADAR: Past, present and future.” Oregon Health and Sciences University. Portland, Oregon. August 2006.
  4. “Clinical trials: Are they a good buy?” Testimony before Missouri State Senate. St. Louis, Mo. August 2006.
  5. Safety Issues & Drug Errors in Oncology: Inadvertent Intrathecal Administration of Vincristine and Reducing Adverse Events in Outpatient Chemotherapy.  Williamsburg, VA. September 2006.
  6. American Society of Clinical Oncology, Clinical Trials Workshop. “Clinical Trials: Are They a Good Buy?” Schaumburg, IL, September 2006. (Meeting Chair)
  7. “Pharmacovigilance: Where are we now?” Annual Community/Academic Oncology Research Forum. Dallas, TX. September 2006.
  8. Introducing the Research on Adverse Drug Events and Reports (RADAR) Project. October 2006.
  9. “Quality of life and drug safety surveillance for cancer patients.” NCI Workshop. Washington, DC. December 2006.
  10. Veterans Administration Health Services Research and Development Service National Meeting. “Augmenting FDA and Pharmaceutical Manufacturer Passive Pharmacovigilance Efforts: Potential Benefit of Collaboration with VA Pharmacovigilance Program.” Arlington, VA, February 22, 2007.
  11. Grand Rounds “Quality of Life Considerations in Prostate Cancer Treatment.” Advocate Lutheran General Hospital, Park Ridge, IL, March 2007.
  12. Society for Clinical Trials. “The Research on Adverse Drug Events and Reports (RADAR) Project.” Montreal, Canada, May 2007.
  13. Grand Rounds “Ticlopidine and clopidogrel-associated TTP: More Different than Similar.” Dept. of Neurology, UIC, Chicago, IL, May 2007.
  14. 44th Annual American Society of Clinical Oncology meeting.  1. “Bisphosphonate use and osteonecrosis of the jaw: Pharmacovigilance and reporting of this serious adverse event from the Research on Adverse Drug Events and Reports (RADAR) project.”(poster discussion)  2. “Recombinant erythropoietin (Epo)/darbepoetin (Darrb) associated venous thromboembolism (VTE) in the oncology setting: Findings from the Research on Adverse Drug Events and Reports (RADAR) project.” (poster) 3. “New IRB guidelines: Will cancer patient safety improve?” (poster discussion) McCormick Place, Chicago, IL, June 2007.
  15. FDA Symposium. “Pharmacovigilance in the post-marketing setting: Results from the RADAR project.” Harvard University, Cambridge, MA, August 2007.
  16. Hematology/Oncology conference presentation. “Pharmacovigilance in the post-marketing setting: Results from the RADAR project”. University of Chicago, Chicago, IL, September 2007.
  17. Gilda’s Club Lecture. “The TEAM Approach in the Management of Prostate Cancer”. Chicago, IL, September 2007.
  18. Grand Rounds Lecture. “RADAR-The 1st Decade”. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, October 2007.
  19. 2007 Clinical Trials Workshop. “Clinical Trials: Are They a Good Buy”.  Grand Hyatt Denver, Denver, CO, October 2007.
  20. NCCN Keynote Address. “Quality and Patient Safety in Oncology”. Wyndham Chicago, November 2007.
  21. Presentation at University of Pennsylvania. “Pharmacovigilance in the Post-Marketing Setting: Results from the RADAR Project”.  November 2007.
  22. Grand Rounds Lecture. “Pharmacovigilance in the Post-Marketing Setting: Results from the RADAR Project”.  Mt. Sinai Hospital, Chicago, IL, December 2007.
  23. Grand Rounds Lecture. “Pharmacovigilance in the Post-Marketing Setting: Results from the RADAR Project. University of Illinois at Chicago, Dept. of Neurology, December 2007.
  24. Clinical & Translational research seminar presentation. “Finding Adverse Drug Effects after FDA Approval: A Post-Marketing Vigilance Study”. Northwestern University, Chicago, IL, January 2008.
  25. Invited Lecture. “Mortality, Venous Thromboembolic Complications, and Antibody-Mediated toxicity of Erythropoietic Stimulating Agents”. Cornell University, NYC, January 2008.
  26. Presentation at the Chicago Urologic Society. “Race, Literacy, and Prostate Cancer”. February 2008.
  27. Presentation at NCCN Annual Conference. “Venous Thromboembolism and Mortality Associated with Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer- Associated Anemia.” Hollywood, Florida, March 2008.
  28. Grand Rounds Lecture. “Navigating medically underserved women through cancer screening and treatment.” Yale University, New Haven, CT, March 2008.
  29. Grand Rounds Lecture. “Pharmacovigilance in the Post-Marketing Setting: Results from the RADAR Project.” Albert Einstein Medical Center, Philadelphia, PA, April 2008.
  30. UPMC Lecture.  “Pharmacovigilance in the Post-Marketing Setting: Results from the RADAR Project. University of Pittsburgh Medical Center. Pittsburgh, PA, April 2008.
  31. Presentation at the World Healthcare Congress. “Consumer and Physician Connectivity.” Washington DC, April 2008.
  32. Presentation at the Prostate Cancer Mini-symposium. “Race, Literacy and Prostate Cancer.” Northwestern University, Chicago, IL, April 2008.
  33. Lecture at the Feinberg Cancer Society lunch talk. “Cancer drugs and their toxicity: Who’s minding the store.” Northwestern Memorial Hospital, Chicago, IL, April 2008.
  34. CAG Conference. “Drug-associated and Idiopathic Thrombotic Thrombocytopenia Purpura (TTP): Results from the SERF-TTP group.” Ottawa, Canada, May 2008.
  35. Presentation at the 2nd Annual Scientific symposium on NSF. “RADAR Overview of NSF: Past, Present and Future Consideration.” Yale University, New Haven, CT, May 2008.
  36. Lecture seminar at UF. “Race, Literacy and Prostate Cancer and Cost-Effectiveness of Colorectal Cancer Screening.” University of Florida, Gainesville, FL, May 2008.
  37. Presentation at the American Urological Association. “Effects f Age, Health-Related QOL and Education Level on Management after Biochemical failure with Watchful Waiting vs. Hormonal Therapy in Men with Prostate Cancer: Results from the COMPARE Registry.” Orlando, FL, May 2008.
  38. Presentation at the Onco-biotechnology Research, Clinical and Business Summit. “Adverse Drug Reactions: Identifying Toxicities of Novel Agents.” Northwestern University, Chicago, IL, July 2008.
  39. Presentation at the EpoR workshop. “Clinical Observations and Guidelines for the Use of Erythropoiesis Stimulating Agens for Cancer Patients.” Bethesda, MD, September 2008.
  40. Presentation at the American Association of Blood Banks annual meeting. “Idiopathic TTP: Predictors of Relapse and Mortality from the SERF (Surveillance Epidemiology and Risk Factors) – TTP Group”. Montreal, Canada, October 2008.
  41. Society for Investigative Dermatology conference. “The Research on Adverse Drug Events and Reports Project”. Washington, DC, October 2008.
  42. Lecture at the Central Texas Veterans Healthcare Hospital. “Prevention and Treatment of VTE: New Strategies and Guidelines for Improving Outcomes.” Temple, Texas, October 2008.
  43. Lecture at MD Anderson.
  44. Presentation at the ESA membership meeting. “Adverse Clinical Observations and Resulting Guideline Reassessments for the Use of Erythropoieses Stimulating Agents.” Hyatt O’Hare, Rosemont, IL, November 2008.
  45. Presentation at the National Patient Navigator Meeting. “A Clinical Perspective of Prostate Cancer”. Atlanta, GA, November 2008.
  46. Lecture at the Signal Detection and Data Mining Event. “The Research on Adverse Drug Events and Reports Project (RADAR)”. Hyatt Regency DC, November 2008.
  47. Grand Rounds Presentation. “Prevention and Treatment of VTE: New Strategies and Guidelines for Improving Patient Outcomes”. St. Vincents Hospital, Indianapolis, IN, December 2008.
  48. Invited Speaker for Wyeth. “TORISEL (temsirolimus) injection: An mTOR Inhibitor for the Treatment of Advanced Renal Cell Carcinoma”. Springfield, IL. December 2008.
  49. Invited Speaker. “Prevention and Treatment of VTE: New Strategies and Guidelines for Improving Patient Outcomes”. Boone Hospital Center, Columbia, MO, December 2008.
  50. Grand Rounds Presentation. “Prevention and Treatment of VTE: New Strategies and Guidelines for Improving Patient Outcomes”. Memorial Hospital, Conway, NH, January 2009.
  51. Invited Speaker. “Prevention and Treatment of VTE: New Strategies and Guidelines for Improving Patient Outcomes”. Oak Forest Hospital, Oak Forest, IL, January 2009.
  52. Invited Speaker. “Prevention and Treatment of VTE: New Strategies and Guidelines for Improving Patient Outcomes”. St. Joseph’s Hospital, Chicago, IL. January 2009.
  53. Invited Speaker. “Prevention and Treatment of VTE: New Strategies and Guidelines for Improving Patient Outcomes”. Good Samaritan Medical Center, West Palm Beach, FL. February 2009.
  54. Invited Speaker. “ESA therapy in nephrology and haemato-oncology: Benefits versus risks and what has the TREAT study taught us?” Royal Society of Medicine, London, England. June 2010.
  55. Invited Speaker. “Conflict of interest in pharmaceutical sponsored basic science research studies: is there any empirical evidence for this?” Prostate Cancer Foundation Annual Retreat, Washington, DC. September 2010.
  56. Invited Speaker. “Possible SafeUse Intervention: reducing barriers to safe prescribing” U S Food and Drug Administration (FDA) SafeUse Initiative Public Workshop, Washington DC. November 2010.
  57. Invited speaker. “Medication Safety in the Geriatric Setting” 10th Annual Geriatric Conference, Columbia, SC. February 5, 2011.
  58. Invited speaker. “Cost-effectiveness Analysis of the Prostate Specific Antigen Exam using the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Data” Prostate Cancer Foundation Scientific Retreat, Lake Tahoe, NV. September 2011.
  59. Grand Rounds hematology/oncology presentation. Adverse DrugReactions. Emory University, Atlanta, GA. November 30, 2011.
  60. Invited presenter. “Realizing the Promise” Charleston, SC. December 2011.
  61. Invited presenter. “Prostate Cancer Treatment: Economic Forecasts of Where We Have Been, Where We Are, and Where We Are Going” Prostate Cancer Update conference Vail, CO. January 28, 2012.
  62. Grand rounds presentation. Introducing SONAR, Palmetto Health Richland, Columbia, SC. March 2012.
  63. Invited presenter/session chair. Patient Centered Medicine Orlando FL. March 2012.
  64. Invited speaker. “Race/ethnicity and Prostate Cancer” Cancer Care Ontario and the Ontario Institute for Cancer Research Sunnybrook Health Sciences Centre, Toronto Canada. May 18, 2012.
  65. Invited speaker. “Planes, cars, oil spills, and pharmaceuticals-- common lessons for preventing major safety tragedies” City of Hope National Medical Center, Duarte, CA. July 18, 2012.
  66. Invited speaker. “Basic science and adverse druge reactions” Children's Hospital Boston Professor of Pediatrics Harvard Medical School, Boston, MA. August 3, 2012.
  67. Grand Rounds presentation. Ohio State University, Columbus, OH. October 4, 2012.
  68. Invited presenter. “Erythropoietin: Basic Science Assessments of What Can Go Wrong With A Blockbuster Cancer Drug” Arizona Cancer Center, Tucson, AZ. January 28, 2013.
  69. Invited presenter. University of Tennessee Health Science Center. Memphis TN. March 12, 2013.
  70. Grand Rounds presentation. “Identifying and Evaluating Fatal Side Effects of Blockbuster Cancer Drugs” St. Jude Children’s Research Hospital, Memphis TN. March 13, 2013.
  71. Grand Rounds presentation. Palmetto Health Richland, Columbia, SC. April 2, 2013.
  72. Invited presenter. “More Harm than Good? When Blockbuster Drugs Cause Tumor Growth, Paralysis or Death”. EngenuitySC’s Science Café series, Columbia, SC. June 11, 2013.
  73. Grand Rounds presentation. “A SONAR report: Adverse effects associated with brentuximab and peginesatide and the association between pharmaceutical support and study conclusions”. Palmetto Health Richland, Columbia, SC. August 15, 2013.
  74. Invited presenter. “Rituximab and biosimilars: Equivalence and reciprocity” 2nd International Conference and Exhibition on Biowaivers and Biosimilars, Raleigh, NC. September 23, 2013.
  75. Invited presenter. “A SONAR Report: Four Unique Studies” Cornell Medical School, New York, NY. May 14, 2014.

 

Charles Lee Bennett

Professor

 

  • :1-312-218-9586
  • Fax:1-803-777-2820
  • DEPARTMENTDepartment of clinical Pharmacy & out comes sciences
    University of South Carolina Campus
  • COUNTRY USA